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One of the most tremendous challenges faced by pharmaceutical scientists is poor 
solubility and/or permeability and the concomitant low bioavailability of new chemical 
entities (NCE). Researchers often find promising candidates during drug screening; 
however, if the molecule exhibits unsuitable physico-chemical properties, the chance of 
delivering the adequate dose to the site of action is diminished. In the last years a negative 
tendency has appeared in the drug discovery pipeline: approx. 70% of NCEs demonstrate 
low solubility and high permeability, therefore belongs to Biopharmaceutical 
Classification System (BCS) II. Conversely, about  only 30% of drugs previously brought 
to the market resides to BCS II  (1). This challenging shift is also expressed in case of 
BCS IV (low solubility and low permeability) compounds: there is an increase of 3-4 
times in favour of NCEs compared to marketed drugs (Fig.1.)  (2). Baicalin -the subject 
of this PhD Thesis- is a bioactive phytopharmacon and can be classified as  
Class IV  (3). In the scientific literature numerous approaches came up to improve the 
low bioavailability of different active pharmaceutical ingredients (APIs). With no claim 
of being exhaustive I would like to notice some of them: cyclodextrin complexation  (4),  
solid dispersions  (5), liposomes  (6), lipid-based formulations  (7), self-emulsifying 
systems  (8). In the following sections a detailed explanation can be found related to lipid-







Figure 1. Trending in Biopharmaceutical Classification System (BCS) 
(http://www.samedanltd.com/magazine/11/issue/158/article/3039; 01/10/2019) 
(BCS I – high solubility and permeability, BCS II – low solubility, high permeability, BCS III – 




In the last decade the pharmacological and formulation aspects of phytopharmacons 
captured the attention of scientist worldwide. This is largely a result of the higher 
tendency among the general population to use complementary and alternative medicine 
and live a health-conscious lifestyle. The motivation behind the topic selection was the 
renaissance of natural products and the challenging physico-chemical and biological 























1.1.Scutellaria baicalensis Georgi (Baical skullcap) 
Scutellaria baicalensis G. (S. baicalensis G.) is one of the fundamental herbs in traditional 
Chinese herbal medicine known as Huang Qin (mandarin: 黄芩)  (9). It is indigenous to 
several East Asian countries (Mongolia, China, Korea) and the Russian Federation and 
has been cultivated in many European countries (Fig.2.)  (10). Baical skullcap is a species 
of flowering plant in the family Lamiaceae. The root is officially listed in the Chinese 
Pharmacopoeia and was assumed in European Pharmacopoeia (Ph. Eur.) 9th Edition in 
2018  (11). The major components in the dried root of the herb are baicalin (D-Glucuronic 
acid-5,6-dihydroxyflavone) and its aglycone, baicalein (5,6,7-trihydroxyflavone)  (12). 
As minor component wogonin (5,7-dihydroxy-8-methoxyflavone) and wogonoside (5,7-
Dihydroxy 8-methoxyflavone 7-glucuronide) can be extracted from the dried root. Heat 
reflux extraction (HRE), ultrasound-assisted extraction (UAE), and supercritical fluid 
extraction (SFE) are common extraction methods to isolate and purify baicalin  (13). 
 
Figure 2. The medical plant of Scutellaria baicalensis (A) and its dried root (B). 
Extracted and purified powder of baicalin (C). 3D structure of baicalin (D). 






1.2.1. General notes 
Baicalin is a flavone glycoside extracted from the root of Scutellaria baicalensis. In 
traditional Chinese medicine it had been used for the treatment of diarrhoea, dysentery, 
haemorrhaging, insomnia, inflammation and different respiratory infections  (10). 
Nowadays baicalin extracts are easily accessible over-the-counter herbal remedies, 
purchasable online and in numerous stores in liquid, bulk powder, capsule or tablet dosage 
form. Recommended daily dosage of powder is 60-500 mg. Baicalin enjoys fairly high 
popularity in ointments, lipsticks and skin care preparations. As a flavonoid derivate, its 
anti-oxidant and anti-aging property can contribute to the skin’s overall quality and 
appearance. Food industry utilizes baicalin as a nutritional adjuvant for improving 
production performance and nourishing feed intake in farm animals  (14).  
 
Figure 3. Growing interest in baicalin as a bioactive phytopharmacon 1982-2019  
Source: PubMed, keyword: baicalin [all] 
 
Baicalin is easily extractable and it has a wide range of therapeutical and pharmacological 
effects (see detailed in section: 1.2.4.), which have brought it into focus as a safe and 
natural phytopharmacon. A PubMed search with the key word Baicalin [all] returns 
approx. 1700 articles from ‘80s to date with 50% of them published in the last five years 
(Fig.3.). Since 2000 the interest in the subject has been increasing gradually. On the one 































as of December 2019. On the other hand, in 2005 the State Food and Drug Administration 
of China approved baicalin (approval No. H20158009) for the adjuvant therapy of 
hepatitis (1500 mg/day, 2 times 3 capsules).  
1.2.2. Physicochemical Profiling  
The most important physicochemical properties influencing the pharmacokinetic 
behavior of drugs and biomolecules are the acid-base properties, lipophilicity, 
permeability and  
solubility  (15). Physicochemical profiling is an integral part of preformulation studies, 
which lays down foundation for transforming a new drug entity into a pharmaceutical 
dosage form in such a way that it can be administered in a right way, in right amount, and 
on the right target  (16). Possessing these kinds of information, the optimization of an 
active molecular entity is also possible.  
The acid-base character determines the ionization state of a molecule in solution having 
a particular pH. Consequently, all pharmacokinetic properties, namely absorption, 
distribution, metabolism, excretion and toxicity (ADMET) are influenced by the 
ionization state under varying pH conditions  (17). Molecular structure of baicalin can be 
derived from its aglycone, baicalein by linking a glucuronic acid to the aglycone via a 
glycosidic bond in position 7 (Fig.4.). It has three acidic functional groups, namely one 
carboxyl (ring: D) and two phenolic hydroxyl groups (ring: A). 
 





Proton transfer processes can be regarded either from the point of view of dissociation or 
association. Because of the acidic nature of baicalin, these processes will be characterized 
by acid dissociation constants (Ka). The determination of pKa value is important in 
understanding the in vivo behaviour of a drug, which influences not only its solubility 
and dissolution, but also the membrane-penetration capacity  (18). The acid-base 
properties of baicalin have been investigated before, resulting in pKa values of 5.05, 7.6 
and 10.1  (19). However, internal Nuclear Magnetic Resonance (NMR) investigations 
showed the molecule rapidly decomposes above pH 9, making the reported values in 
alkaline solutions highly dubious.  
The determination of the octanol/water partition coefficient (log P) is essential during 
preformulation studies, which is in close correlation with membrane-penetration 
capability and is the most frequently determined lipophilicity descriptor  (20). There have 
been attempts in characterizing the lipophilicity of baicalin ((log P=1.27 (pH=7)), but the 
applied methods and study design can induce doubts  (19). It is not exactly clear what the 
authors meant by this, probably they calculated the log P of baicalin from log D measured 
at pH 7. Therefore, the data provided is to be considered as indicative only. However, if 
we accept with restrictions the above-mentioned value, the lipophilicity of baicalin must 
be considered as low. Calculation of log P value provides data regarded to passive 
diffusion through biological membranes, but it does not describe properly the carrier-
mediated active transport mechanisms. The Caco-2 monolayer is isolated from human 
colorectal adenocarcinoma and widely used across the pharmaceutical industry as an in 
vitro model of the human intestinal barrier to predict the active and passive absorption 
mechanisms of orally administered drugs  (21). The permeability potential of baicalin 
was evaluated by Caco-2 assay (Papp 9.2×10
-8 cm/s), which revealed low permeability  
(22). The low lipophilicity and permeability value of baicalin presumes low absorption 
from the gastro-intestinal tract (GIT). 
Aqueous solubility is a fundamental attribute of an active substance and its examination 
is a mandatory step during the drug discovery process. To achieve adequate plasma drug 
levels and clinical response, dissolution of the active ingredient in physiological 
environment is a leading precondition. New drug molecules as well as phytopharmacons 
tend to have larger molecular weights, resulting often in decreased solubility and 




and log P values of baicalin, its aqueous solubility is also marked by discrepancies in the 
scientific literature; 0.18 mg/ml, 0.08 mg/ml and 0.052 mg/ml can be found  (23–25). 
Furthermore, the factors affecting solubility (e.g. temperature, pH, ionic strength, surface 
tension) were not investigated yet in a comprehensive study. It can be seen from the 
chemical structure that both the glucuronide and the flavone part forms intramolecular H-
bonds, which can be partly responsible for the poor water solubility and high melting 
point  (26). If an oral drug is under development, particularly one with low solubility, 
biorelevant measurements are extremely useful because through simple in vitro tests they 
can predict how it's likely to dissolve in vivo in the GIT. Over the past 15–20 years, 
biorelevant media simulating conditions in the stomach and small intestine before and 
after meals have been developed  (27). Simulated intestinal fluid in fasted state (FaSSIF) 
and in fed state (FeSSIF) along with fasted state gastric fluid (FaSSGF) have been 
suggested first by Dressman et al  (28). In addition, the application of these media can be 
used to predict food effects  (29). In case of baicalin these kind of physiologically relevant 
solubility data have not been published yet.  
The chemical stability of baicalin was evaluated in buffered aqueous solutions at different 
pH (2.0, 3.0, 4.5, 6.8, 7.4 and 9.0) and temperatures (4, 25 and 40 °C). Acidic environment 














1.2.3. Biopharmaceutical properties 
Several studies described the pharmacokinetics of baicalin according to the ADME 
concept. The absorption mechanism was evaluated in rats by Liu et al. and found that 
baicalin was moderately absorbed in the stomach but poorly in the small intestine and 
colon  (31). More research pointed out that baicalin undergoes extensive hydrolysis by 
intestinal β-glucuronidase or intestinal microbiome to form its aglycone, baicalein 
(Fig.5.). 
 
Figure 5. Role of transporters in transport of baicalin in enterocytes (Interaction of 
baicalin with transporters, Bernadett Kalaposné Kovács, Semmelweis University, 2016) 
 
Since the aglycone is absorbed much more better compared to baicalin, this cleavage 
reaction has a potent role in the absorption process  (32, 33). Baicalin is substrate of 
uptake transporter organic anion-transporting polypeptide 1B1 (OATP1B1)  (33). In the 
intestinal enterocyte baicalein is transformed to baicalin, and effluxed to the blood mainly 
by multidrug resistance associated protein 3 (MRP3) and MRP4, located on the 
basolateral side of the cell  (33). Accordingly, after administration of a single ascending 




baicalin were about ten-fold higher than Cmax values of baicalein  (34). Part of baicalin is 
pumped back to the intestinal lumen by apically located MRP2 and breast cancer 
resistance protein (BCRP)  (35).  
In the distribution mechanisms of baicalin the high plasma protein-binding capacity (86-
92%) plays a prominent role  (36). Wei et al. revealed the tissue distribution of baicalin 
after intravenous administration of liposomal and injectable formulations to rabbits. 
Liposomal drug delivery indicated a significantly increased lung accumulation compared 
to injectable solution  (37). Baicalin penetrates moderately through the blood-brain-
barrier (BBB)  (38).  
Validated method was applied to analyse and screen the in vivo metabolism of baicalin in 
rats. No less than 32 metabolites were identified in the rat plasma and urine. The results 
demonstrated that the rat liver and kidney are the most important organs for the 
distribution of baicalin metabolites. Methylation, hydrolysis, hydroxylation, 
methoxylation, glucuronide conjugation, sulphate conjugation, and their composite 
reactions were all identified  (39).  
Baicalin is primarily excreted in bile in the form of glucuronides and undergoes a 
prominent enterohepatic recycling through different ABC transporters  (33, 40). As an 
alternative excretion pathway, the fraction of baicalin excreted in urine appears to be 
negligible compared to the biliary route  (41). 
1.2.4. Pharmacological effects 
Baicalin has numerous pharmacological activities demonstrated by in vitro and in vivo 
studies among others anti-inflammatoric, anti-allergic, anti-depressant, anti-microbial, 
anti-oxidant as well as anti-psoriatic effects  (42–47). Ding et al. showed that baicalin 
relaxes vascular smooth muscle and lowers blood pressure in spontaneously hypertensive 
rats by regulating KATP channels and the intracellular Ca
2+ level  (48). It was revealed that 
long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis 
in rats given a high-fat diet  (49). Baicalin might serve in the future as a novel compound 
in the treatment of the most common neurodegenerative diseases in elderly patients, the 
Parkinson’s  (50). The preliminary results suggest that the mechanism of action is a 




hyperglycaemia-induced cardiovascular malformation of embryos in mice. The 
cardiovascular abnormality can be attenuated by baicalin administration. This compound 
is a promising candidate for women suffering from gestational diabetes  
mellitus  (51). Cancer is one of the leading causes of death worldwide and is very likely 
to overtake heart diseases, which has traditionally topped the list as the leading cause of 
death in higher income countries. Scientific projects reveal an ever-increasing number of 
evidence that baicalin exhibits its antitumor function in a wide range of cancers such as 
breast cancer, colon cancer, gallbladder carcinoma, haematological malignancies, hepatic 
cancer, lung cancer, prostate cancer  (52–57). The chemical modification of the baicalin 
aglycone pointed out promising development in preclinical studies  (58). Therefore, the 
chemical and pharmacological optimization and the production of semisynthetic derivates 
could be an interesting research direction in the future. It is important to note that 
extensive clinical studies are needed for the confirmation of the above mentioned in vitro 
and in vivo results.  
1.2.5. Baicalin-drug interactions 
Several studies have been carried out on the effects of baicalin and co-administered drugs. 
Remarkable baicalin-drug interactions can be observed, when both compounds share the 
same cytochrome P450 (CYP) enzyme or exhibiting high plasma protein binding. The 
relevant preclinical and clinical research findings and the mechanism of herb-drug 
interactions are summarized in Table I.  
Two clinical trials can be found in the literature regarding baicalin-drug interactions. Liu 
et al. executed the first clinical study to investigate the effect of baicalin on cyclosporine 
A pharmacokinetics in humans (n=16)  (59). The applied dosage was 500 and 200 mg in 
case of baicalin and cyclosporine A, respectively. The combination was well-tolerated 
and the pharmacokinetic behaviour of cyclosporine A was not changed to a clinically 
relevant extent. The reported adverse events were mild and the data didn’t lay down 
evidence that baicalin co-administration with cyclosporine A would cause an additional 
risk. Fan et al. analysed the pharmacokinetics of rosuvastatin, an antihyperlipidemic drug 
co-administered with baicalin. In the study 18 healthy adults were enrolled, possessing 
various organic anion-transporting polypeptide 1B1 (OATP1B1) haplotypes  (60). 




The volunteers received placebo or 50 mg baicalin 3 times a day for 14 days than on the 
15th day, all subjects were given a single oral dose of 20 mg rosuvastatin. It was revealed 
that baicalin reduces systemic plasma exposure of rosuvastatin in an OATP1B1 
haplotype–dependent manner. Baicalin treatment was well-tolerated in the administered 
dose and can be considered as safe.  





Mechanism of herb-drug 
interaction 
Ref. 
Caffeine CYP1A, CYP2B ↓ 
Conc. of baicalin was not 
enough to inhibit CYP enzymes 
 (62) 
Chlorzoxazone 
Cmax↓, t1/2↑, V↑, CL 
Ø AUC Ø 
Competition for plasma protein 
binding and CYP2E1 inhibition 
 (63) 
Cyclosporine A Ø No relevant interaction  (59) 
Dextromethorphan 
Cmax↑, t1/2 Ø, V↓, 
CL↓, AUC↑ 
Competition for plasma protein 
binding and CYP3A inhibition 
 (64) 
Midazolam 
Cmax↑, t1/2↑, V↓, 
CL↓, AUC↑, 
CYP3A inhibition  (65) 
Nifedipine 
Cmax↓, V↑, CL↑, 
AUC↓ 
Competition for plasma protein 
binding and CYP3A inhibition 
 (66) 
Phenacetin 
Cmax↓, t1/2↑, V↑, 
CL↓, AUC↑ 
Competition for plasma protein 
binding and CYP1A2 inhibition 
 (67) 
Rosuvastatin t1/2↓, CL↑, AUC↓ OATP1B1 induction  (60) 
Theophylline 
Cmax↓, t1/2↑, V↑, CL 
AUC depends on 
regime 
Competition for plasma protein 
binding and CYP1A2 inhibition 
 (68, 69) 
Abbreviations: Cmax: peak plasma concentration, t1/2: terminal half-life, V: apparent volume, CL: 
clearance, AUC: area under the curve, OATP1B1: organic anion-transporting polypeptide B1,  








1.2.6. Bioavailability enhancement  
Baicalin has diversified pharmacological effects, however its low solubility and 
permeability along with the concomitant poor bioavailability precludes sufficient oral 
administration. It was pointed out that the absolute bioavailability of baicalin is 2.2 ± 
0.2% in rats  (40). In order to overcome the physico-chemical and pharmacokinetic 
limitations of baicalin, the development of novel drug delivery systems (DDS) and 
formulations has attracted an increasing attention in the pharmaceutical field. Summary 
of innovative formulations are listed in Table II.  






Excipients used Ref. 










Glycerol monostearate, oleic acid, 
polyethylene glycol monostearate 
 (72) 
Nanoemulsion 7.0 
Soy-lecithin, Tween® 80, PEG 400, 





Peceol™, Kolliphor® EL, Transcutol® P, 




- α-, β-, γ-, HP-β-, SBE-β-, RAMEB-CD  (3) 
Solid dispersion 3.38, 1.83 
Polyvinyl-pyrrolidone, Mesoporous 
carbon nanopowder 
 (75, 76) 
Mixed micelle 
system 




Chitosan, Glycerophosphate, PEG 6000, 






1.3. Lipid-based formulations 
Lipid-based drug delivery (LBDD) have gained much importance in the recent years due 
to their ability to improve the solubility and bioavailability of drugs with poor water 
solubility. Lipid formulations generally consist of a drug dissolved in a blend of two or 
more excipients, which may be triglyceride oils, partial glycerides, surfactants and/or co-
surfactants. The absorption of drug from these formulations depend on numerous factors, 
e.g. particle size, degree of emulsification, rate of dispersion and precipitation of drug 
upon dispersion  (79). These systems increase absorption from the gastrointestinal tract 
by accelerating the dissolution process (rate-limiting liberation step is excluded), 
facilitating the formation of solubilized phases by reduction of particle size to the 
molecular level, changing drug uptake, efflux and disposition by altering enterocyte-
based transport, and enhancing drug transport to the systemic circulation via intestinal 
lymphatic system  (7). Pouton et al. introduced the Lipid Formulation Classification 
System (LFCS) in 2000 (Tbl. III.). The foundation of LFCS rests on the principle of the 
polarity of the blend and differentiates 4 types. Preparations which comprise drug 
dissolved in triglycerides or mixed glycerides, require digestion in GIT are classified as 
Type I. Adding water insoluble surfactants to the oily phase may improve the solvent 
capacity of the formulation. Self-emulsifying systems are classified as Type II, which 
emulsifies into crude oil in water emulsion in aqueous solutions under gentle agitation. 
There is a threshold in surfactant content at approx. 25% (w/w); passing this value the 
progress of emulsification is compromised by viscous liquid crystalline gels. Preparations 
which include water-soluble components are classified as Type III formulations, and have 
been referred as self-microemulsifying systems (droplet size <200 nm), due to the optical 










Table III. The Lipid Formulation Classification System 
 
Co-administration of emulgents and co-emulgents induces significant higher 
solubilisation capacity in vivo compared to co-emulgent free preparations  (80). Type III 
systems can be split into Type III/A and Type III/B depending on the oil: hydrophilic 
content ratio. One of the first Type III products on the market was Sandimmune Neoral®, 
a supergeneric reformulation of immunosuppressant cyclosporine A  (81). Some years 
later, Pouton and his research group integrated in the classification system a new oily 
phase free category (Type IV), which disperses to form a micellar solution and remains 
relevant in case of highly hydrophobic compounds  (82). However, the high surfactant 
and co-solvent content should not be forgotten, because it may be poorly tolerated in 
chronic use. The choice of formulation requires detailed analysis and depends on several 
factors: dose, type and molecular weight of drug, stability of drug in various excipients, 
significance of emulsified droplet size, risk of precipitation due to high surfactant content, 
solubilisation capacity, digestion by intestinal enzymes  (7). Table IV indicates some 
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Table IV. FDA approved products formulated by lipid-based systems 
API/ 
trade name 


























Paraffin, mineral oil, squalene 






 lipid levels 
Corn oil glycerides, Kolliphor® RH 40, 

















4 IV HIV 
Vitamin E TPGS, PEG 400  

















1.4.Self-emulsifying Drug Delivery Systems 
Self-emulsifying Drug Delivery Systems (SEDDS) are isotropic mixtures 
(preconcentrates) of drugs, natural/synthetic oils, hydrophilic/lyophilic emulgents and 
optionally hydrophilic co-emulgents. Following their oral intake and dilution in gastric 
juice, the gentle agitation of GIT creates a fine oil in water (o/w) type emulsion (Fig.6.). 
SEDDS present the drug in a dissolved form, excluding the rate-limiting dissolution step. 
The onset of action is rapid but it can be sustained by application of polymers. Effective 
solubilisation is a key attribute of emulsified systems in order to avoid precipitation of 
drug in GIT. Important aspect the small droplet size in case of micro-, and nanoemulsions 
provide a large interfacial area for drug absorption. Further advantages of SEDDS are 
high drug loading capacity, ease of manufacture and scale-up, protection of sensitive 
drugs and decreased food effects  (83). A distinction is made between SEDDS, Self-
Nanoemulsifying Drug Delivery Systems (SNEDDS) and Self-Microemulsifying Drug 
Delivery Systems (SMEDDS) on the basis of emulsified droplet size, thermodynamic 
stability of droplets and preconcentrate composition.  
 
Figure 6. Composition and conception of Self-emulsifying Drug Delivery Systems 
(self-made) 
1.4.1. Microemulsions and nanoemulsions: similarities and differences  
After dilution in the GIT, SMEDDS or SNEDDS form the corresponsive microemulsions 
and nanoemulsions. Because of their biopharmaceutical and therapeutical advantages, 
these are the two most common types of colloidal dispersions  (84). Furthermore, they 
exhibit better stability against aggregation and sedimentation along with the potential for 
industrial scaling-up  (85). These superior properties materialize in colloidal systems 
possessing a droplet size <200 nm in diameter  (86). It is usually easy task to define a 
macroemulsion (e.g. droplet size, composition, optical properties), but how to distinguish 
between microemulsions and nanoemulsions? Currently, there is a considerable 














there are many structural similarities between these two kinds of colloidal dispersion, but 
there are also basic differences  (87).  
The terminology commonly used to refer micro-, and nanoemulsions is misleading. Micro 
is a unit prefix denoting a factor of 10-6, nano means 10-9. At first glance one could believe 
that there is a three order of magnitude disparity in size between them, which is far from 
the truth. In practice the opposite is usually the case: the particles in a microemulsion are 
smaller than those in a nanoemulsion. The answer for this discrepancy lies within the 
development of colloidal chemistry. The first scientific article using the term 
“microemulsion” was published in 1961, whereas first article related to “nanoemulsion” 
appeared in 1996. The term “microemulsion” spread among researchers well before the 
introduction of term “nanoemulsion”, and before they were clearly defined or 


















The most meaningful difference between the systems in question is the thermodynamic 
standpoint: microemulsion forms spontaneously as a thermodynamically stable 
dispersion, contrary to nanoemulsion which requires minimal energy input  (88). The free 
energy of a microemulsion (droplets in water, ΔGcoll.disp.) is lower than the free energy of 
separate phases (oil and water, ΔGow), so the self-emulsification of these formulations are 
thermodynamically favourable (ΔGcoll.disp. <ΔGow). The situation is reversed for 
nanoemulsions: the free energy of the colloid dispersion is higher compared with the 
separated phases (ΔGcoll.disp.> ΔGow), so the creation of nanoemulsion is energetically 
unfavourable (unstable thermodynamics) (Fig.7.).  
 
Figure 7. Demonstration of the free energy (ΔG) of nanoemulsion and microemulsion 
compared to the phase separated state. Microemulsions have a lower free energy than 
the phase separated state, whereas nanoemulsions have a higher free energy. (self-made) 
 
In spite of their thermodynamic instability, nanoemulsions are able to put up aggregation 
resistance for months during storage; the system will persist in a metastable state. If there 
are sufficient energy barriers separating the two phases, the coalescence of 
nanoemulsified dispersion will be slow and sustained. The height of the needed energy 
barrier is mainly determined by physicochemical phenomena that prevent the droplets 
from coming into close proximity, such as repulsive hydrodynamic and colloidal (e.g., 




concluded that the higher the energy barrier is, the more expressed the kinetic stability. 
There are a lot of various physicochemical phenomena which can lead to the breakdown 
of a nanoemulsion (e.g. flocculation, creaming, Ostwald-ripening, coalescence)  (90). The 
role of stabilizer excipients such as weighting agents, surface active agents, texture 
modifiers, polymers is essential in the long-term stability of colloidal dispersions  (91).  
 
Table V. Comparison of microemulsion and nanoemulsion 
 
From the point of view optical properties, the droplet size is decisive: the system begins 
to clear up around 200 nm and turns transparent under 60 nm  (92). Nanoemulsions tend 
to have spherical structure because of the large Laplace pressure. Within that size range 
the surface tension (γ: N/m) is high, while particle radius (r: m) is low, therefore -
according to Law of Laplace (∆𝑃 =
2𝛾
𝑟
)- significant Laplace pressure can be detected. A 
sphere has the lowest interfacial area and concomitant surface tension for a given volume 
of material, that is the reason behind nanoemulsions favoured character  (86). 
Character Microemulsion Nanoemulsion 
Thermodynamic stability Stable Unstable 
Kinetic stability Unstable, but compensated 








Higher emulgent/oil ratio 
Emulgent with low 
molecular mass 
Lower emulgent/oil ratio 
Proteins, polymers, 
emulgents with high 
molecular mass 
Optical properties Clears up around 200 nm, turns transparent under 60 nm 
Particle-size distribution 
Single, narrow peak, low 
polydispersity 






Microemulsions exhibit a wide range of shapes (e.g. worm-like, bicontinuous sponge-
like, liquid crystalline, or hexagonal, spherical swollen micelles). Influencing factors are 
type and quantity of incorporated oil and surfactant, and the ideal curvature of utilized 
surfactant(s) (Tbl. V.)  (93). In this thesis I am primarily focus on microemulsions and 
nanoemulsions that can be used to encapsulate lipophilic components, that consist of 
small spheroid particles comprised of oil and surfactant molecules dispersed within water. 
Other kinds of microemulsion systems (e.g. liquid crystalline, worm-like) are out of the 
scope of this thesis.  
It is important to distinguish between microemulsions and nanoemulsions in practice 
since this predispose their long-term stability, functionality, robustness against altered 
environmental conditions (temperature, relative humidity, dilution) and bioavailability. 
Some practical methods provide data which category a colloidal dispersion belongs to. 
Composition, particle size distribution studies, long-term storage measurements 
supplemented with altering environmental conditions, particle shape analysis might be 
















1.4.2. Role of excipients in the formulation of SEDDS 
The utilized excipients have a definitive influence on self-emulsification, stability and 
drug delivery (Fig.8.). Chemical structure and concentration of oil and emulgent, 
oil/emulgent ratio, quality and quantity of co-emulgent, emulgent/co-emulgent ratio, 
weigh-in order, temperature, ionic strength were shown to have significant effect on the 
quality of SEDDS  (94). It is clear that a lot of parameters must be considered to fulfil the 
critical quality attributes of SEDDS: 
• Solubility of API in the oily phase must be maximal 
• Achieve in the various physiological conditions of GIT constant droplet size and 
stability 
• Toxicity, purity, stability, price, acquisition of excipients are important criteria  
• Improved bioavailability by reduced droplet size and enhanced absorption via 
lymphatic transport and solubilisation  
 









Oils are the most significant components of SEDDS, which promote self-emulsification, 
facilitate drug absorption through the mucosal membrane and allow the dissolution of 
large amounts of lipophilic substances. The solubilisation capacity of GIT is also 
enhanced by using lipid components because they stimulate pancreatic and bile juice 
excretion  (95). Oils can be classified as natural, semi-synthetic and synthetic derivates. 
According to their chemical structure we can distinguish between triglycerides and mixed 
glycerides (mixture of mono-, di-, and triglycerides) esterificated by medium or long-
chained fatty acids (saturated/unsaturated). Natural oils are derived primarily from plant 
sources comprised of mixtures of triglycerides which contain fatty acids of varying chain 
lengths and degrees of unsaturation (e.g. soy oil, sunflower oil, coconut oil, olive oil). 
Their main advantage is the fully digestion and absorption in the GIT mediated by 
physiological enzymes and therefore they are generally regarded as safe (GRAS). The 
acceptance of patients is also higher in case of natural medicines and excipients. The low 
resistance to oxidation and decreased solvent capacity compared to semi-synthetic and 
synthetic derivates are challenging formulation issues  (7). 
Semi-synthetic and synthetic oils are partial glycerides, prepared by glycerolises, a 
transesterification reaction of triglycerides in order to increase the hydrophilic character 
of natural oils. There are several modified oils on the market: glyceryl-
monocaprylocaprate (Capmul® MCM); glyceryl-monostearate (Geleol™, Imwitor® 191, 
Cutina™ GMS, Tegin™); glyceryl-distearate (Precirol™ ATO 5); glyceryl-monooleate 
(Peceol™); glyceryl-monolinolate (Maisine™ 35-1); glyceryl-dibehenate (Compritol®888 
ATO). PEGylated polyoxylglycerides are also available: oleoyl macrogol-6 glycerides 
(Labrafil® M 1944CS), lauroyl Macrogol-32 glycerides (Gelucire® 44/14). Numerous 
research groups investigated the relationship between solubility and bioavailability of 
API and structure of oil  (96–98). The components, process parameters and conclusions 
were different and therefore does not enable unambiguous interpretation. They pointed 
out as a collective and general experience that the incorporated active substance has a 






Surfactants are amphiphilic molecules that lower the surface tension, meaning they 
contain both hydrophilic and hydrophobic groups. Emulsifiers are indispensable 
components of SEDDS as they strengthen drug absorption by altering the lipid bilayer 
organization, enhance the lipid-intestinal membrane interactions, dissolve hydrophobic 
substances between their hydrocarbon chains and moreover kinetically stabilize the 
droplet size distribution  (99). Application of higher surfactant concentrations don’t 
always reduce droplet size of colloidal dispersion, formed after dilution of SEDDS 
preconcentrate in GIT, but may even increase it. The phenomenon can be attributed to the 
increased water penetration, and concomitant disruption of interfacial film, which causes 
oil droplets to be expelled into external water phase  (82). Surfactants are classified into 
cationic, anionic, zwitterionic and non-ionic types. It was revealed that non-ionic 
surfactants demonstrating lower toxicity and have better tolerability in case of chronic 
use compared to ionic ones  (100). Hydrophilic-lipophilic balance (HLB) is an important 
indicator for the characterization of surfactants that quantifies the oil and water attracting 
capacity of the surface-active molecule. Using 30-70 % (w/w) emulgent provides 
colloidal SNEDDS/SMEDDS dispersions with long-term physical stability and narrow 
particle-size distributions  (101). From the point of view self-emulsification, the preferred 
HLB value should be higher than 12  (102). The HLB for a mixture of emulsifiers is 
calculated in proportion to the concentrations. Droplet size analysis was demonstrated as 
a suitable method for the determination of required HLB value in lemon oil emulsions  
(103). A special property of non-ionic surfactants is cloud point, the temperature above 
which the surfactant phase separates and precipitates out of solution. The cloud point is 
higher than 37 °C in ideal case because of the risk of irreversible phase separation in the 
body  (104). Furthermore, it was demonstrated that several emulgents have an inhibitory 
impact on different CYP-enzymes and on intestinal P-glycoprotein, which phenomena 
can be used to enhance the bioavailability in special cases  (105). Some of the typically 
used surface active agents in SEDDS formulations are macrogolglycerol-ricinoleate 
(Kolliphor® EL), macrogolglycerol-oleate (Labrafil® M 1944 CS), caprylocaproyl 
macrogol-8 glycerides (Labrasol®), propylene glycol monocaprylate type II (Capryol® 





Co-solvents are integral part of SEDDS. They initiate self-emulsification, increase the 
elasticity of interfacial film, lower interfacial tension, allow the dissolution of remarkable 
amount of API and prevent formation of liquid crystals  (106). Co-surfactants can also be 
used to fine-tune the formulation phase behaviour, for example, by expanding the 
temperature or salinity range of microemulsion formation. In general, the optimal applied 
concentration lies between 20 and 50 %(w/w). Application of co-surfactant is not 
mandatory at all, several studies focused on cosolvent-free formulations  (107, 108). 
Ethanol, propylene glycol, Transcutol® P and PEG400 are some of the widely used co-
surfactants. 
 
1.5.Transformation of liquid SEDDS/SMEDDS/SNEDDS into solid dosage 
forms  
Transforming liquid self-emulsifying preconcentrates to solid carriers is a strategy in 
lipid-based formulation design, which besides solubility improvement, offers further 
advantages over liquid systems; increased long-term physicochemical stability, ease to 
scale up, processability, precise dosing and improved patient compliance  (109). 
However, it is important that the solidification procedure must preserve self-emulsifying 
properties and small droplet size which have to be demonstrated by reconstitution studies 
during formulation development. The most relevant solidification methodologies are 
spray drying, extrusion-spheronization and adsorption onto porous solid carriers  (110). 
Adequate drug loading, compatibility, suitable drug release profile, processability are 
critical quality attributes of carriers used for converting liquid SEDDS to solid dosage 
forms  (111). Oral delivery of pH-, and enzyme-sensitive biologics may be achieved by 
solid SEDDS formulated with special environment responsive excipients. The basic 





Figure 9. Formulation and analysis possibilities of solid SEDDS (self-made) 
 
Extrusion-spheronization 
Extrusion-spheronization is an agglomeration technique involving multiple processes for 
the preparation of matrix pellets. A compromise between the smallest amount of 
adsorbent material needed and the largest amount of liquid SEDDS required is essential 
to produce pellets with good physical characteristics and highest possible drug loading  
(112). Sticking of extrudate, friable and soft pellets, challenging spheronization process 
and decreased porosity are the main consequences of high liquid SEDDS content  (113). 
Reconstitutability and self-emulsifying properties of matrix pellets were confirmed in 
several studies  (114, 115). The order of components mixing was identified as a critical 
parameter for a successful extrusion/spheronization process and for the roundness value 
of pellets  (116). Colloidal silicon dioxide, microcrystalline cellulose and lactose were 
successfully utilized for the preparation of self-emulsifying matrix pellets. HLB value of 
emulgent in liquid phase influences the processability and mechanical properties of 
pellets. Matsaridou et al. pointed out that the required water quantity for pelletization rose 
linearly with increasing HLB values  (117). Furthermore, the higher the HLB, the faster 
the disintegration time. Extrusion-spheronization method is suitable for the production of 
modified release dosage forms. It can either be carried out by formation of a slowly 
dissolving matrix structure (e.g. HPMC, PVP) that delay release of the drug or by coating 




Adsorption onto porous solid carriers 
The simplest and most intensively investigated method to formulate solid SEDDS is 
adsorption to highly porous solid carriers. Generally used carriers for adsorption of liquid 
SEDDS are:  
• silicon dioxide; fumed silica with different grades of specific surface (Aerosil®) 
or micronized amorphous silica with different grades of pore volume (Sylysia®);  
• magnesium aluminometasilicate with different surface properties (alkaline or 
neutral) and particle size (Neusilin®)  
• porous dibasic calcium phosphate anhydrous (Fujicalin®) and 
• microcrystalline cellulose  
Combined application of these carriers have been reported as effective approach for 
producing solid SEDDS with adsorption method  (119). Relative simplicity, absence of 
organic solvents, easy scale up, high drug loading and small number of solid excipients 
needed are advantages of adsorption method  (120). Drug loading is in close correlation 
with carrier’s oil adsorbing capacity; even loadings up to 80 % have been reported; 
nevertheless, general value is about 50%  (121). Beg at al. evaluated the oil adsorbing 
capacity of various porous carriers, which declines in the following order:  
Sylysia® 350 > Neusilin® US2 > Sylysia® 550 > Sylysia® 730 > Aerosil® 200  (122). High 
drug loading and high oil adsorbing capacity are not associated always with superior 
bioavailability. Yeom et al. pointed out that SEDDS formulated with low oil adsorbing 
capacity mannitol had better bioavailability compared to other carriers  (123). Particle 
size, porosity (length and diameter of pores), type and amount of adsorbent along with 
the specific carrier-SEDDS interactions like wettability play a crucial role in dissolution 
kinetics and drug release. The effect of wettability, the affinity between lipid components 
and surface of solid carriers was highlighted by hydrophilic (Aerosil® 200) and 
hydrophobic porous silica particles (Aerosil® R972) with similar nanostructures  (124). 
The surface interactions were significantly greater between hydrophobic particles and 
lipid components, which was confirmed by only 33% nifedipine release, compared to 
80% of hydrophilic silica particles. Thus, the remarkable hydrophobic forces can be 
utilized to sustain the solubilisation of lipophilic drugs. However, these interactions have 




counterbalance using superdisintegrant in the formulations  (125). Complete drug release 
can be also hampered due to gel formation and clogging of pores  (126). 
Spray drying 
Spray drying is a well-known gentle, rapid, cost-effective and scalable process in 
pharmaceutical industry, where the dry powder is made from a fluid material by 
atomization it into a hot drying gas, usually air. For the production of solid SEDDS 
sufficient carriers are needed that can influence drug release and oral bioavailability of 
incorporated drug  (127). Low yield and the stability issue of volatile cosurfactants (e.g. 
Transcutol®, ethanol) due to relative high drying temperature must be kept in mind during 
formulation development  (128). Further limiting factor for this technique is the viscosity 
of SEDDS; it must be low enough to enable spraying onto the carrier. Several 
hydrophobic (colloidal silica, magnesium stearate) and hydrophilic (e.g. maltodextrin, 
dextran, HPMC, lactose, poly vinyl alcohol) carriers were investigated for spray dried 
solid SEDDS. Controlled drug release from solid SEDDS can be obtained by water-
soluble carriers, which exert erosion and swelling-dependent drug release mechanisms. 
Yi et al. prepared nimodipine-loaded solid SEDDS stabilised with HPMC of various 
viscosities. Formulation with higher HPMC viscosity demonstrated a reduced release rate 
due to the inhibition of drug diffusion through dense polymer matrix and sustained 
polymer erosion  (129). Prevention of in vivo drug precipitation can be achieved by adding 
polymers like gelatine and Soluplus® to the dispersion to be spray dried  (130). 
1.6.Cyclodextrin complexation 
Cyclodextrins (CDs) are cyclic oligosaccharides composed of α-1,4-linked D-
glucopyranose units possessing a hydrophilic exterior and hydrophobic cavity, where 
lipophilic molecules can form a non-covalently bonded inclusion complex  (131). 
Although they have been discovered in the early 1890s, the attention was drown to CDs 
in the 1980s with the first application in the pharmaceutical and food industries  (132). 
These molecules can operate and become widespread as excipients throughout the whole 
industrial and agricultural sector. In pharma industry CDs are used for the improvement 
of water-solubility and bioavailability of medicinal products. They are used for example 




industry their taste masking and flavour stabilizing along with food preservative effect is 
utilized  (133). In agriculture CDs are applied for improvement of the physico-chemical 
characteristics of pesticides, extension of shelf-life and reduction of environmental 
pollution  (134).  
1.6.1. Short history of Cyclodextrins 
Antoine Villiers French pharmacist described in 1891 the formation of unexpected 
crystals with particular properties during a potato starch fermentation reaction by Bacillus 
amylobacter. Villiers concluded that the properties of these special dextrins were very 
clearly different from those of the various saccharides known at that time  (132). The next 
exciting scientific result of CD research was linked to the work of Austrian Franz 
Schardinger. In two publications (1903, 1911) he described the preparation, separation 
and purification of Dextrin A and B, which he classified as cyclic polysaccharides  (135). 
His hypothesis regarded to the cyclic structure of Dextrin A and B was confirmed in 1948 
by Freudenberg et al. Friedrich Cramer introduced first the term “cyclodextrin” (1956) 
and provided numerous data on cyclodextrin host-guest complexes and basic 
physicochemical characteristics  (136). The “CD bomb” was exploded in the 1980’s: the 
nontoxicity of CDs became increasingly accepted, and several manufacturers started to 
produce and to market CDs. The first CD-containing product, a prostaglandin E2/β-CD 
(Prostarmon E™) sublingual tablet was launched in Japan, 1976. Since then a great 
number of patents, publications and products were the outcome of CD inclusion 
complexes to enhance solubility, improve stability and increase bioavailability of drugs. 
Today the annual CD production is over 10000 tonnes and CDs can currently be found in 
over 60 marketed pharmaceutical products (Tbl. VI.)  (137). Traditionally, CDs are used 
as excipients, however several research groups all over the world are investigating their 
potential as active pharmaceutical ingredients. Bridion® (modified γ-CD by placing eight 
carboxyl thio ether groups at the sixth carbon positions) and HP-β-CD, which are used 
for reversal of neuromuscular block in anaesthesia and for the treatment of fatal genetic 
Niemann Pick Type C disease, a cholesterol metabolism disorder, respectively. The latter 






Table VI. FDA approved pharmaceutical products with cyclodextrins 
Drug CD Trade name Dosage form 
Alprostadil α-CD Edex® Injection 
Piroxicam β-CD Brexin® Tablet 
Omeprazol β-CD Omebeta® Enteric capsule 
Metronidazole β-CD Flagyl® Vaginal gel 
Aripiprazole SBE-β-CD Abilify® I.m. solution 
Ziprazidone SBE-β-CD Zeldox® Capsule 
Itraconazole HP-β-CD Sporanox® Oral solution 
Mytomicin HP-β-CD MitoExtra® I.v. infusion 
Chloramphenicol RAMEB Clorocil® Nasal spray 
Minoxidil γ-CD Alopexy® Hair solution 
 
Abbreviations: HP-β-CD ((2-hydroxypropyl)-β-CD), RAMEB-CD (random methylated β-CD) (SBE-β-CD 






















1.6.2. Physicochemical characteristics of Cyclodextrins 
Naturally occurring parent CDs are crystalline, homogeneous, nonhygroscopic 
substances, which are toroidal macro-rings built up from glucopyranose units. α, β, and γ 
CDs comprise of 6, 7, and 8 glucopyranose units, respectively, and differ in their 
molecular weight, cavity size, and solubility (Fig.10/A., Tbl. VII.). There are bigger CDs 
composed of 9 (δ-CD), 10 (ε-CD), and 11 (ζ-CD) glucose units, but their practical 
suitability is negligible in the field of pharmaceutical sciences  (139). The glucopyranose 
units adopt a 4C1 conformation and orient themselves so that the molecule forms the 
aforementioned torus-like geometry. The consequence of this geometry is that the CD 
molecule has a hydrophilic (exterior) surface and a considerably less hydrophilic 
(interior) microenvironment in its cavity  (140). 
 
 
Figure 10. Chemical structure of α-, β-, and γ-CD (A). Schematic demonstration of CD 







The polarity of the cavity has been estimated to be similar to that of aqueous ethanolic 
solution. This attribute gives CDs the opportunity to host molecules possessing low water 
solubility (Fig.10/B.). All secondary hydroxyl groups are situated on one of the two rims 
(“wider”) of the ring, whereas all the primary ones are placed on the other rim 
(“narrower”)  (141). These hydrophilic groups are outside of the molecular cavity, 
whereas the inner surface has a less hydrophilic character due to the ether-like anomeric 
oxygen atoms and the skeletal carbon atoms. 
Table VII. Physicochemical properties of parent and derivate cyclodextrins (self-made) 
Property α-CD β-CD γ-CD HP-β-CD RAMEB 
SBE-β-
CD 
Glucose units 6 7 8 7 7 7 
Molecular weight 
(g/mol) 









0.57 0.78 0.95 0.78 0.78 0.78 
Internal cavity 
height (nm) 
0.78 0.78 0.78 ~ 0.78 ~ 0.78 ~ 0.78 
Cavity volume 
(nm3) 
0.174 0.262 0.472 ~0.262 ~0.262 ~0.262 
Solubility (mg/ml) 158 185 232 > 500 >600 >500 
 
Substitution of any of the hydrogen bond-forming hydroxyl groups of native CDs, even 
by lipophilic functions, results in a dramatic improvement in their aqueous solubility, 
referred as CD derivates  (141). The modification of natural (parent) CDs generally aims 
at converting them into amorphous, non-crystallisable derivatives, to provide high CD 
concentration in aqueous solutions. Number of CD derivates exceeds 11.000, but new 
types are permanently developed  (142). At present, α-CD, β-CD, γ-CD, HP-β-CD, 
RAMEB and SBE-β-CD are used in medicines on the European market  (143). According 
to regulatory requirements, the extent of substitution must be defined to avoid any 
misunderstandings. Conventionally, the so-called average degree of substitution (DS) is 
used, which gives the average number of substituted hydroxyls of a glucose unit  (142). 
One of the largest developer, producer and supplier of CD derivates and a pioneer in CD-




1.6.3. Formation of drug-cyclodextrin inclusion complex 
Cyclodextrin molecules are able to form non-covalently bounded drug-CD complexes 
and therefore to host lipophilic moieties into the cavity (Fig.9/B.). There is a dynamic 
equilibrium between the molecules bound in the complex and the free drug molecules in 
solution. Higuchi and Connors’ phase-solubility method is used to study the effect of 
cyclodextrin concentrations on drug solubility and to describe the complexation process 
(Fig.11.)  (144).  
 
Figure 11. Types of phase-solubility isotherms according to Higuchi and Connors (self-
made) 
 
Abbreviations: AL: linear diagram; AP: positive deviation from linearity; AN: negative deviation from 
linearity; BS: the complex has limited solubility; BI: insoluble complex; S0: intrinsic drug solubility. 
 
In cases when the formed complex is insoluble (BI), the solubility of the guest remains 
unaltered until all guest molecules converted into insoluble CD complex; thereafter a 
decrease in the concentration of dissolved drug can be detected. A typical BS-type 
solubility curve is, where the initial ascending portion is followed by a plateau region and 
then a slight decrease in total drug solubility accompanied by precipitation of complex. 
If the solubility limit of complex is higher than the studied CD concertation range, the 




stoichiometry, while AP-type represents a positive deviation from linearity indicating a 
continuous rise in the stoichiometry of complex. AN-type isotherm can be described by 
complex processes: either the host ratio within the complex increases or there is a change 
in solvent-solute interactions (ionization, hydrolysis), or both contribute at the same time 
(145).  
The complex formation is a reversible process and can be described with the following 
equitation:  
𝑚 × D + 𝑛 × CD 
𝐾𝑚:𝑛
↔  [D𝑚CD𝑛]                                                                                           
(1) 
where m drug molecules (D) associate with n cyclodextrin (CD) molecules to form a 
complex of m:n stoichiometry. Km:n is the observed stability constant of the complex, also 
known as the binding constant, formation constant, or association constant. Rearranging 






If the intrinsic solubility (S0) of drug is defined as drug solubility without CD and the 
formed complex is D-CD, then: 
[𝐷] = 𝑆0 
 (3) 
[𝐷]𝑇𝑜𝑡𝑎𝑙 = 𝑆0 + [𝐷 − 𝐶𝐷] 
(4) 
where [D]Total is the total drug solubility assuming 1: 1 complex stoichiometry. Plotting 
[𝐷]𝑇𝑜𝑡𝑎𝑙 against [𝐶𝐷]𝑇𝑜𝑡𝑎𝑙 gives a linear function, where the intercept is 𝑆0, the slope of 




𝑆0  ×  (1 − 𝐵)
 
(5) 





1.6.4. Toxicological assessment and regulatory status of Cyclodextrins 
The safety and toxicity of cyclodextrins depend on the route of administration and dose. 
Due to their molecular weight and relative high hydrophilicity, CDs are not absorbed 
from the GIT, therefore oral administration is basically considered as safe. For parenteral 
use, α-, HP-β-, and SBE-β-CD are approved and regarded as safe. Intravenously 
administered CDs are rapidly removed from the systemic circulation and are renally 
excreted (146). In case of heterobranched CD-derivates, a transglycosylation step is 
possible. The haemolytic effect of CDs has been reported in many in vitro publications. 
Irie and Uekama pointed out that the haemolytic effects of various CD derivatives and 
parent CDs decrease in the order of β-CD > HP-β-CD ≥ α-CD >> γ-CD, whereas SBE-β-
CD was nonhaemolytic  (147). However, the clinical relevance of haemolytic side effect 
is negligible. In animal studies after oral administration α-, β-, HP-β, SBE-β-, and γ-CD 
mild side effects like soft faeces, diarrhoea or cecal enlargement were observed. These 
side effects can be attributed to a high intake of poorly indigestible carbohydrates  (148). 
The negative effect of CDs on kidney is well-known for a long time. It was demonstrated 
that host-guest complexes of cholesterol/CD enter by glomerular filtration and are then 
taken up by the kidney tubular cells, where the insoluble cholesterol aggregates cause 
kidney damage  (148). It is important to note that the different CDs have different renal 
toxicity. No observed effect level (NOEL) was shown in case of α-, HP-β-, SBE-β-, and 
γ-CD administering 75 mg/kg, 50 mg/kg, 80 mg/kg and 200 mg/kg intravenous injection 
daily for a month in rats, respectively  (149, 150). RAMEB and β-CD, however, generates 
irreversible cell injury and kidney dysfunction and thus are not suitable for medicinal 
products given intravenously  (151). EMA has reported a guideline summarizing the 
approved cyclodextrin-containing formulations depending on administration route 
considering the clinical and non-clinical data (Tbl. VIII.)  (143). Furthermore, it proposes 








Table VIII. Approved cyclodextrin types depending on administration route  (143) 
 
The regulatory status of cyclodextrins vary greatly from country to country (Tbl. IX.). In 
the EU, Japan and USA an approved claim can be found for α-, β-, and γ-CD as food 
ingredients. Parent cyclodextrins as well as CD derivates are listed as pharmaceutical 
excipients in the EU, Japan and USA. The monograph of SBE-β-CD is already referenced 
in the Japanese Pharmaceutical Codex (JPC) and U.S. Pharmacopoeia (USP) and will be 
included in the European Pharmacopoeia (Ph. Eur.) next year. 
Table IX. Regulatory status of cyclodextrins in foods and pharmaceuticals 
  Regulatory status in food Regulatory status in pharmaceuticals 























Monograph Monograph Monograph 
HP-β-
CD 
- - - Monograph Monograph Monograph 
SBE-β-
CD 
- - - - Monograph Monograph 
Regulation (EC) N° 1223/2009 on cosmetic products is the main regulatory framework 
for finished cosmetic products when placed on the EU market. CosIng is the European 
Commission database for information on cosmetic substances and ingredients contained 
in the Regulation (EC) N° 1223/2009. 
Route α-CD β-CD γ-CD HP-β-CD RAMEB SBE-β-CD 
Oral  X X X  X 
Parenteral X   X  X 
Dermal  X X X   
Nasal     X  
Ocular  X  X X  




According to the database as of 12/12/2019, 12 Cyclodextrins are referred and approved 
as cosmetic substances (chelating, viscosity controlling, emulsion stabilizing, skin 
conditioning, absorbing, surfactant) in the EU: 
1. Acetyl cyclodextrin 
2. Cyclodextrin crosspolymer 
3. Cyclodextrin Hydroxypropyltrimonium Chloride 
4. Cyclodextrin laurate 
5. Dimaltosyl Cyclodextrin 
6. Hydroxyethyl Cyclodextrin 
7. Hydroxypropyl Cyclodextrin 
8. Maltosyl Cyclodetrin 
9. Methyl Cyclodextrin 
10. Sodium Cyclodextrin Butylsulfonate 
11. Sodium Cyclodextrin Sulfate 
12. Sodium Hydroxypropyl Cyclodextrin Octenylsuccinate 
 
1.6.5. Methods of preparation of inclusion complexes 
In the scientific literature one can find numerous approaches for the preparation of drug-
CD inclusion complexes. On the one hand, the selected method along with the process 
parameters applied considerably influences the final product. On the other hand, an 
optimized and efficient complexation is needed for the demanded improved dissolution 
rate and greater bioavailability enhancement  (152). The most popular techniques 
available for the inclusion preparation can be divided on the basis of complex state; a) 
methods in solution, b) methods in semisolid state and c) methods in solid state (Fig.12.).  
Methods in solution 
There are extensive data about the different solution methods, where drug and CD is 
perfectly dissolved in purified water and/or organic solvents. Temperature, pH and ionic 
strength are critical parameters for the appropriate interaction between the compounds. 
One option is the rapid cooling down of equilibrated mixture to precipitate out of solution 




adding antisolvent, which precipitates the complex. Other opportunity is the removal of 
solvent(s) from the system via solvent evaporation (154), spray drying  (155, 156) or 
freeze drying  (157, 158). Appreciable drawback of these procedures is the general 
organic solvent demand and time-consuming attribute. When using organic solvents, the 
formulation has to be always evaluated for residuals.  
Methods in semisolid state 
Hot-melt extrusion (HME) is a recognized, continuous process for manufacturing of solid 
dispersions and innovative dosage forms. HME is also a suitable method for creating 
paste-like extrudates containing drug-CD complexes. The API, CD and amorphous 
polymer are fed into the extruder, conveyed, exposed to shear inside the extruder and 
subsequently the extrudate is pressed out through a die. Yano and Kleinebudde used HP-
β-CD to improve the dissolution behaviour of indomethacin by HME  (159). Thiry et al. 
studied HME to form CD-itraconazole (ITZ) complexes using different CDs in a 1:1 
(CD:ITZ) molar ratio  (160). It was revealed that the polymer is not only a matrix forming 
agent, but also increase the stability of inclusion complex  (161).  
Simple kneading is a possibility to formulate a homogenous pasty product, where the 
drug-CD physical mixture is kneaded with moistening agent (water/ethanol) in a high-
shear granulator (industrial scale) or in a mortar (laboratory scale). This is followed by 
drying and sieving of the powder. Nonetheless, such a method often results a low 
complexation ratio  (153). 
Methods in solid state 
The complexation process can be initiated by microwave irradiation (MWI), by gentle 
heating or by mechanochemical activation through grinding with mortar-pestle 
combination or with different types of mills. The disadvantage of thermal stimulation is 
the potential degradation of API. Grinding, on the other hand, gives the opportunity to be 
a cheap, fast and highly effective method for the formulation of drug-CD inclusion 
complexes in the solid state, generally without using of organic solvents. He et al. carried 
out the molecular encapsulation of rifampicin into HP-β-CD by simple manual grinding 
using mortar and pestle creating an amorphous product with 2.5 times higher solubility 




planetary ball mills operated with alternating periods (overall time from 1 to 5 h) to 









Figure 12. Frequently used formulation processes of drug-CD inclusion complex  
(self-made) 
 
Li et al. used planetary ball mill for the preparation of bisacodyl-β-CD complex, where 
the process parameters were 5 h process time (5 min run and 1 min pause) at 400 rpm in 
50 ml agate jar. The end product was fully amorphous and indicated better solubility 
compared to complexes formulated by co-evaporation or freeze-drying  (163). High-
energy vibrational mills and tumbling ball mills are seldom used for this purpose.  
 
 
Methods in solution 
Crystallization 
a) Cooling  
b) Antisolvent  
c) Co-Evaporation 
d) Spray drying 
e) Freeze-drying 
Methods in semisolid state 
a) Hot-melt extrusion 
b) Kneading 
 







• Planetary ball mill 
• Tumbling ball mill 
• Vibrational mill 




1.6.6. Pharmaceutical application of cyclodextrins 
The complex-forming ability, special shape and structure along with the extensive 
formulation possibilities laid the foundation of cyclodextrin application in field of 
pharmaceutical technology and industrial pharmaceutics. Cyclodextrins were first 
described by Villiers in 1891, however, the first pharmaceutical product including 
cyclodextrin as excipient was marketed 85 years later in Japan (see detailed in Section 
1.6.1.). 130 years after their discovery a marked progress has been made, but CDs are still 
regarded as pharmaceutical excipients of enormous unexploited potential  (137).  
The most characteristic application field of CDs is the solubility enhancement of 
lipophilic drugs with poor water solubility. Furthermore, wettability of apolar surfaces, 
dissolution time and complex stability is also increased. API-CD complexes compared to 
other solubilization techniques have several beneficial properties:  
• Due to the lack of surfactants, the tissue irritation and further side effects can be 
avoided. 
• The risk of precipitation on dilution in GIT juices is practically negligible.  
• Numerous administration routes can be applied (e.g. per oral, dermal, ocular, 
parenteral, nasal, as well as drug targeting formulations). 
• Inside the cavity of CD, acid sensitive drugs can be stabilized and protected. 
•  In this context, a reliable, non-invasive delivery of proteins (e.g. insulin) and 
formulation of CD-siRNA-conjugates have been successfully demonstrated. 
 
In addition, the CD complexation is utilized in many more fields of pharmaceutical 
technology and analytics: 
• Tissue toxicity and irritative potential of drugs are reduced.  
• Physical, chemical and photochemical stability are ameliorated. 
• Odour and taste masking effect. 
• Shelf-life and effect of volatile substances (aromatics, fragrances, essential oils) 
are sustained. 
• Cyclodextrin crosspolymers due to their swellability have a potential as 




• CDs are naturally chiral molecules; therefore, they are the most frequently used 
chiral additives for the separation of various enantiomers. 
• In the elimination of residual solvents, impurities, degradation products CDs are 
































The main objective of this work was to formulate and develop baicalin-loaded DDS in 
order to counterbalance the negative physicochemical and pharmaceutical properties of 
baicalin. For this challenging task, the preformulation studies of the drug were put in the 
focus, which provided strong basis for the development, optimization and comparison of 
baicalin-cyclodextrin inclusion complexes and of baicalin-loaded self-emulsifying DDS. 
Considering the above mentioned, my aims were the followings: 
1. Quantify the most important biorelevant physicochemical properties of baicalin 
in terms of acid/base, lipophilicity and thermodynamic solubility in different 
compendial and physiological media. Explore its polymorphism and crystal 
structure, crystal habit, particle size, thermal behaviour. 
2. Preparation and comparative evaluation of various baicalin-CD inclusion 
complexes. In order to reveal the molecular interactions inside the cavity and to 
characterize the 3D geometry of the complex, each species was subjected to phase 
solubility, 1H NMR and 2D ROESY experiments along with molecular modelling 
of the binding pattern into cyclodextrins. Comparison of computational study and 
experimental results were also in my interest. 
3. Enhance the poor aqueous solubility and dissolution rate via a liquid self-
nanoemulsifying drug delivery system. Find an optimized carrier system for 
baicalin, and to analyse and characterize the reconstituted nanoemulsion using 
AFM, droplet size, and Zeta-potential measurements, long-term stability tests, and 
in vitro dissolution studies. Elaborate a sample preparation method for AFM 
imaging of nanosized droplets was also a substantial goal. 
4. Transform liquid self-emulsifying preconcentrates to solid carriers and prepare 
self-nanoemulsifying matrix pellets by extrusion-spheronization method. Identify 
the critical process parameters and reveal the relationships. Analyse the physical 
state of baicalin in the solid dosage form and follow the incidental alteration(s) in 
time. Examine the drug release and the reconstitutability of droplets by in vitro 







Baicalin (batch number:BA-16118) was supplied by Actin Chemicals, Inc. (Chengdu, 
China). Sodium taurocholate, lecithin, pepsin, indicator molecules for the NMR-pH 
titrations (TRIS, acetamidine hydrochloride and 1-methylguanidine hydrochloride) were 
purchased from Sigma-Aldrich (Budapest, Hungary), the deuterated solvent D2O from 
VWR International (Debrecen, Hungary) and the DMSO-d6 from Euriso-top (Saint-
Aubin, France). The following materials were donated by Gattefossé (Saint Priest, 
France) and were used as received: Capryol® 90 (Propylene glycol monocaprylate), 
Labrafac™ Lipophile WL 1349 (Medium-chain triglycerides), Labrafil® M 1944 CS 
(Oleoyl polyoxyl-6 glycerides), Labrasol® (Caprylocaproyl polyoxyl-8 glycerides), 
Lauroglycol™ 90 (Propylene glycol monolaurate), Maisine® CC (Glyceryl 
monolinoleate), Peceol™ (Glyceryl monooleate (type 40)), Transcutol® P (Dyethylene 
glycol monoethyl ether). Kolliphor® EL (Polyoxyl 35 hydrogenated castor oil), 
Kolliphor® RH40 (Polyoxyl 40 hydrogenated castor oil), Olive oil, Emprove® (Absolute 
ethanol) were purchased from Sigma Aldrich (St. Louis, USA). Sunflower oil was 
supplied by Hungaropharma (Budapest, Hungary). GalenIQ™ 800 (Isomalt) was kindly 
gifted by Beneo Palatinit GmbH (Mannheim, Germany). Avicel® PH 101 was supplied 
by DuPont Nutrition & Biosciences (Midland, USA). All CDs (α-CD, β-CD, γ-CD, (2-
hydroxypropyl)-β-CD (HP-β-CD), random methylated β-CD (RAMEB-CD) and 
sulfobutylether-βCD (SBE-β-CD)) were kindly donated by Cyclolab R&D Ltd. 
(Budapest, Hungary). Other chemicals of analytical grade were obtained from 
commercial suppliers and used without further purification. Bidistilled water was used 










3.2.Preparation of compendial and biorelevant media 
The pH value of each solution was controlled with a Hanna® pH 210 microprocessor pH 
meter (Hanna Instruments, USA) and media were prepared according to literature at room  
temperature  (27).  
A total of 0.94 g of 1 M HCl and 0.35 g of NaCl were diluted and dissolved to 1000 ml 
with distilled water and used as simulated gastric fluid (SGF) with pH 1.2. A total of 250 
ml of 0.2 M K2HPO4 and 77 ml of 0.2 M NaOH were homogenized and diluted to 1000 
ml with distilled water. This medium served as simulated intestinal fluid (SIF) with pH 
6.8.  
Blank buffer of FaSSGF pH 1.6 (1.99 g NaCl dissolved in 900 ml distilled water, adjusted 
the pH to 1.6 with 1 M HCl and filled to 1000 ml with distilled water) and phosphate 
buffer pH 6.5 (0.42 g NaOH pellets + 3.95 g NaH2PO4 monohydrate + 6.19 g NaCl 
dissolved in 900 ml distilled water, adjusted the pH to 6.5 with either 1 M NaOH or 1 M 
HCl and filled to 1000 ml with distilled water) were prepared as stock solutions.  
FaSSGF was produced from blank buffer of FaSSGF pH 1.6, which was completed by 
0.08 mM sodium taurocholate, 0.02 mM lecithin, 0.1 mg/ml pepsin and has osmolality of 
120 ± 2.5 mOsmol/kg. To obtain the FaSSIF medium, 100 ml of blank phosphate buffer 
(pH 6.5) was made up by 3 mM sodium taurocholate and 0.75 mM lecithin. FaSSIF has 
an osmolality of 270 ± 10 mOsmol/kg.  
3.3.Preformulation studies 
3.3.1. Determination of Thermodynamic Solubility by Saturation Shake-
Flask Method  
The thermodynamic solubility of baicalin in various media was determined by saturation 
shake-flask method based on the method of Baka et al.  (164). Briefly, 10 mg of baicalin 
was added to 5 ml of each solvent in sealed vials. All samples were stirred (approx. 500 
rpm) and thermostated (IKA RT-5 power heatable magnetic stirrer, IKA Work Inc., USA) 
at 37 ± 0.5°C for 24 h allowing it to achieve thermodynamic equilibrium. After this 
period, 24 h of sedimentation cycle was adopted without stirring at 37 ± 0.5°C. To 
improve the efficacy of phase-separation, the saturated supernatant of samples was 




Germany). The aliquots (250 μl) taken for solubility experiments were suitably diluted 
with blank buffers and the absorbance was measured at λ = 316 nm by UV spectroscopy 
(Agilent 8453 UV-Visible Spectrophotometer, Agilent Technologies Ltd., USA). The 
drug exhibited absorption maxima (λmax) at 214, 279 and 316 nm in distilled water. 
Ideally, λmax selected for the analysis of drug should not show any interference due to 
solvents and excipients present in the dissolution medium. At 279 nm, baicalin showed 
higher molar absorptivity; however, this wavelength was not selected for the 
quantification of the drug because there was interference of excipients in biorelevant 
media at this wavelength. In the solubility study, thus, λmax 316 nm was selected for the 
quantification of baicalin. In case of the distribution study, the above-mentioned obstacle 
did not appear, so λmax 279 nm could be easily used. All experiments were repeated three 
times and results were calculated from the linear calibration curve of baicalin in each 
media. Data are expressed as mean ± SD (μg/ml). 
3.3.2. Acid-base properties  
NMR-pH titrations were performed on a Varian VNMRS spectrometer (600 MHz for 1H). 
Spectra were recorded at 25°C. Titrations were carried out in solutions containing 95% 
(v/v) H2O and 5% (v/v) D2O, with the addition of small amounts of 0.1 M HCl and NaOH. 
One molar NaOH and solid NaOH crystals were also used to achieve highly basic pH 
values. The ionic strength was kept at 0.15 M by the presence of NaCl. The concentration 
of baicalin and its methyl ester was 1.0 × 10−3 M and ascorbic acid was used in large 
excess (5.0 × 10−3 M) to prevent the oxidation of the studied catechol molecules in 
alkaline solutions. The sample volume was 600 μl. NMR spectra were referenced to the 
internal standard DSS (sodium 3- (trimethylsilyl)-1-propanesulfonate). The water signal 
was suppressed by presaturation. Spectra were processed with VNMRj 3.2a software. pH 
values were read on a Metrohm 2.780.0010 precision pH meter with a 6.0258.600 
Unitrode glass Pt 1000 electrode (Metrohm AG, Herisau, Switzerland). The pH-
potentiometric system was calibrated using pH 1.68, 4.01, 6.87, 9.18 aqueous buffer 
solutions. In highly basic solutions, pH was measured by NMR-pH indicator molecules 
as well to avoid the uncertainty of the glass electrode pHmeter readings in such solutions  




titration curves of proton chemical shifts versus pH, the software Origin Pro 8 (OriginLab 
Corp., Northampton,MA, USA) was used. 
3.3.3. Distribution Coefficient Measurements by the Stir-Flask Method  
The distribution coefficients were calculated from the absorbance of the molecules before 
and after partitioning at several octanol/water phase ratios  (166). For the pH control, a 
pH 7.40 phosphate buffer and a standardized HCl solution were used, with an ionic 
strength of 0.15 M in both cases. The pH of the phosphate buffer was measured using a 
Metrohm 6.0204.100 combined pH glass electrode and a Metrohm 780 pH meter. The 
concentration change of baicalin was followed by UV-absorbance measurements. 
Because of the poor water solubility in acidic solutions, the absorbance of the octanol 
phase (with an initial baicalin concentration of 4.2 × 10−5 M) had to be monitored in the 
partition experiments with 0.15 M HCl. However, at pH 7.40, the solubility in water was 
high enough to follow the concentration change of baicalin in the aqueous phase, starting 
from the initial concentration of 5.6 × 10−5 M. Several water/octanol phase ratios were 
used, depending on the pH and the expected log D value, to ensure that the absorbance of 
baicalin after partitioning should become approximately half as much as the original value 
before partitioning. Then, the two phases were intensively stirred for 2 h in thermostated 
double-walled glass cells at constant temperature (25 ± 0.1°C). After separation of the 
equilibrated phases and centrifugation, the concentration of baicalin was determined by 
UV spectrophotometry (Perkin-Elmer Lambda 15) at several values at 279 nm (λmax). The 
distribution coefficients were calculated from the absorbance of baicalin before and after 
partitioning. 
3.3.4. Crystal habit 
The external shape and morphology of individual crystals were characterized by Scanning 
Electron Microscopy (SEM). SEM images were collected from the surface of individual 
particles operating JSM 6380LA Series Scanning Electron Micrpscope (JEOL Inc., 
USA). Accelerating voltage varied from 5 kV to 10 kV and spot size from 8 to 10 
depended on the electrostatic charge-up of microstructured surface. 100–500 times of 
zoomed in images have been taken for particle size determinations and 1000–3000 times 




3.3.5. Particle size analysis 
Particle size of baicalin was determined by Laser Diffractometry (LD) method with the 
instrument Mastersizer 2000 laser diffractometer (Malvern Instruments Ltd., UK). 
Sample preparation involved dispersing 3.00 w/w% baicalin and 0.50 w/w% Polysorbate 
80 solution into demineralized water and dilute it to 100.0 ml. The dispersion was poured 
into Mastersizer Hydro SM small volume dispersion unit at a mixing speed of 1500 rpm, 
which yielded 10 % laser obscuration. Sample absorbance was measured prior particle 
sizing by an 8453-type, single beam UV-Vis spectrophotometer, (Agilent Technologies, 
USA) on wavelength λ max = 633 nm, which is the wavelength of red He-Ne laser beams, 
found in instrument Mastersizer 2000 laser diffractometer. Laser diffraction measurement 
was performed based on Mie scattering theory, pre-set measurement parameters including 
refractive index of baicalin 1.739, refractive index of dispersant water 1.333 were utilized 
with general purpose measurement enhanced sensitivity mode, which is suitable for 
sample characterizations containing irregular shaped particles. Every sample was 
measured five times individually and the mean ± standard deviation values are reported. 
Each measurement took 20 seconds to perform suggested by the Malvern diffraction 
application v.5.60.10.0 (Malvern Instrument Ltd., UK), to allow slow moving larger 
aggregates to pass through the detector array. 
3.4.Baicalin-Cyclodextrin inclusion complexation 
3.4.1. Phase solubility studies 
The phase solubility studies were carried out according to the method of Higuchi-Connors  
(167). Experimentally, an excess amount of baicalin (10 mg, 2.25 mM) was added to 
increasing concentrations (5, 10, 20, 40, 80 mM) of various distilled water-based CD 
stock solutions at pH 4.5 (in case of β-CD—because of its low aqueous solubility—1.25, 
2.5, 5, 7.5, 10 mM stock solutions were prepared). The vials were agitated by 
ultrasonication (Branson 5200, Danbury, USA) for 4 h followed by 72 h of equilibration 
phase (25°C). After sedimentation, the saturated supernatant was taken and centrifuged 
at 14,000 rpm for 15 min with Herolab MicroCen 16 centrifuge (Herolab GmbH, 
Wiesloch, Germany). Samples were suitably diluted with distilled water and drug 
concentration was obtained via UV spectroscopy at wavelength 279 nm (Agilent 8453 




repeated three times and results were calculated from the linear calibration of baicalin in 
distilled water (R2 = 0.9992). Assuming 1:1 complex stoichiometry, the stability constants 
(K1:1) of baicalin-CD inclusion complexes were calculated based on phase solubility 
diagrams according to Higuchi-Connors (eq. 5). 
3.4.2. Signal Assignment of Baicalin and Characterization of Baicalin-
Cyclodextrin Inclusion Complexes Using 1H NMR and 2D ROESY 
Experiments  
Assignment and CD complexation NMR experiments were recorded at 25°C on a Varian 
Mercury Plus spectrometer at 400 MHz. For complete signal assignment, 15 mg of 
baicalin was dissolved in 0.6 ml DMSO-d6 and transferred to 5 mm NMR tube. For the 
investigation of inclusion complexes, cyclodextrin was dissolved in 0.7 ml D2O and 
baicalin was dissolved in 0.3 ml DMSO-d6; these two stock solutions were mixed and 
sonicated; after 72 h, an aliquot of 0.6 ml was transferred into a 5-mm NMR sample tube. 
The resulting solution was at 2.5 mM concentration for both compounds. Reference 
baicalin solution was made by the same method without CD. In the beginning of the 
experiments, minimal precipitation was observed. Therefore, the concentration of 
baicalin in the final solution was reduced from 10.0 to 2.5 mM, in which concentration 
was still enough for the characterization of baicalin-cyclodextrin inclusion complexes and 
gave sufficient signal/noise ratio. Chemical shifts are given in ppm and are referenced to 
the residual solvent signal (DMSO-d6: δH = 2.50 ppm;  
δC = 39.50 ppm). For investigation of inclusion complexes, 1H spectrum was taken from 
64 scans, 24 k data points, the sweep width was 6400 Hz. For the ROESY spinlock, a 
mixing time of 400 ms was used; the number of scans was 16 and 4 k time domain points 
and 256 increments were applied. For complete assignment, 32 scans, 32 k data points 
and 6400 Hz spectral width were used for 1H measurement and 16,384 scans, 64 k data 
points and 24,154 Hz sweep width were applied for 13C measurement. In case of the 
gHSQC spectrum, data points were acquired with 1 k × 512 and 4 scans were used. In the 
gHMBC experiment, 1 k × 256 data points and 8 scans were applied. gCOSY 
measurement was taken from 1 k × 256 data points and 8 scans. The processing was 





3.4.3. Molecular Modelling of the Binding into Cyclodextrin  
All computations were carried out with the Gaussian09 program package (Gaussian Inc., 
USA, Wallingford CT, 2009) using convergence criteria of 3.0 × 10−4 , 4.5 × 10−4 , 1.2 × 
10−3 and 1.8 × 10−3 , for the gradients of the root mean square (RMS) force, maximum 
force, RMS displacement and maximum displacement vectors, respectively. The 3D 
structures of various cyclodextrin structures, like β-CD, γ-CD, RAMEB-CD and SBE-β-
CD as well as their complexed forms with baicalin were optimized at B3LYP/6-31G(d) 
level of theory and compared to each other  (168). 
3.5.Liquid Self-nanoemulsifying Drug Delivery Systems 
3.5.1. Solubility Studies  
The thermodynamic solubility of baicalin was determined in distilled water, different oils, 
emulgents, and co-emulgents by saturation shake-flask method with minor modifications  
(164). Firstly, an excess amount of baicalin was added to 2 g of each excipient in sealed 
vials. All samples were stirred (approx. 500 rpm) and thermostated (IKA RT-5 power 
heatable magnetic stirrer, IKA Work Inc., Wilmington, DE, USA) at 37 ± 1 ◦C for 24 h. 
Secondly a cycle of sedimentation (to achieve separation of the excess solid from the 
solution) was carried out for 24 h at 37 ± 1 ◦C. To improve the efficacy of phase-
separation, the saturated supernatant of samples was centrifuged at 14,000 rpm for 15 min 
using a centrifuge (Herolab MicroGen 16, Herolab GmbH, Wiesloch, Germany) followed 
by removal of the incidentally undissolved baicalin from the supernatant by filtering it 
with a nylon membrane filter (0.22 µm, 25 mm, FilterBio® NY, Labex Ltd., Budapest, 
Hungary). Samples were suitably diluted with absolute ethanol and drug concentration 
was obtained via UV spectroscopy at wavelength 279 nm using equivalent proportions of 
excipients as blank (Agilent 8453 UV-Visible Spectrophotometer, Agilent Technologies 
Ltd., Santa Clara, CA, USA). All experiments were repeated three times and results were 
calculated from the linear calibration of baicalin in absolute ethanol (R2 = 0.9991). Data 







3.5.2. Screening of Surfactants for Emulsifying Ability  
Various surfactants (Capryol® 90, Kolliphor® EL, Kolliphor® RH 40, Labrafil® M 1944 
CS, Labrasol®, Lauroglycol™ 90) were screened for emulsification ability with the 
selected oily compound. According to pre-formulation experiments, different 
oil:emulgent w/w ratios (1:3, 1:4, 1:5, 1:6) were created, and selection of the emulgent 
was based on the results of droplet size and transmittance analysis. Briefly, 1 g of pre-
concentrate was prepared in sufficient quantities, gently stirred, and heated to 37 ± 1 ◦C, 
promoting the homogenization process. The isotropic mixture, 0.1 mL, which was 
accurately weighed and diluted to 100 mL with distilled water, yielded fine emulsions. 
Emulsions were equilibrated for 2 h at room temperature before measuring their 
transmittance by Agilent 8453 UV-Visible Spectrophotometer at wavelength 633 nm 
using distilled water as blank. The droplet size (Z-avg) distribution and polydispersity 
index were measured by dynamic light scattering (DLS) method with the instrument 
Zetasizer Nano ZS™ (Malvern Instruments Ltd., Malvern, UK). Measurement settings 
were: automatic mode, NIBS (none-invasive-back-scattering) 173◦, 30 sub 
runs/measurements, run duration of 10 s, automatic laser position selected, 4.65 mm 
position from the bottom of the cuvette, attenuation setting of attenuator 9 was selected 
automatically. Five measurements with 30 runs were performed for every sample and the 
mean ± SD values are reported in this article for all DLS parameters, including intensity-
weighted mean hydrodynamic diameters (Z-avg) and polydispersity index (PDI).  
3.5.3. Construction of Ternary Phase Diagram  
In order to identify the self-nanoemulsifying compositions with the desired droplet size  
(Z-avg < 200 nm), a ternary phase diagram was constructed  (169). For every mixture, 
the surfactant and co-surfactant (Smix) ratios were varied from 1:1, 1:2, 1:3, and 2:1. 2 g 
of the oil and Smix in different w/w ratios (1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, and 
2:1) were measured, blended for 1 h at approximately 500 rpm (IKA RT-5 power heatable 
magnetic stirrer), and heated at 37 ± 1 ◦C. Compositions were evaluated for nanoemulsion 
formation by dropping 100 µL of each of the 40 mixtures in glass beakers containing 100 
mL distilled water that was maintained at 37 ± 1 ◦C, followed by Z-avg measurements 




the ternary phase diagram was constructed using the ProSim ternary diagram drawing 
application (ProSim, Toulouse, France).  
3.5.4. Preparation of Self-Nanoemulsifying Formulations without 
(SNEDDS) and with Baicalin (BSNEDDS)  
In all cases, oil, emulgent, and co-emulgent were thermostated at 37 ± 1 ◦C and stirred 
(approximately 500 rpm) in different w/w ratios by a heatable magnetic stirrer. After a 1-
h homogenization cycle, they were stored at room temperature in sealed vials until further 
use. BSNEDDS were prepared by the above-mentioned method, but at the end of the 
homogenization cycle, baicalin was added to the optimized pre-concentrate (C = 2.5 
mg/mL). 
3.5.5. Optimization of SNEDDS Preconcentrates  
In order to reduce the number of trials needed in the optimization of SNEDDS 
formulation, and to characterize the relationship between the formulation factors and the 
output variables, a response surface methodology based on Face Centered Central 
Composite Design was utilized. The amount of oil and Smix ratio can significantly 
influence the quality and performance of a nanoemulsion, so different oil:Smix (1:8, 1:6, 
1:4) ratios and emulgent:co-emulgent (1:1, 2:1, 3:1) ratios were analyzed as formulation 
variables (X1, X2). In the study, a three-level (coded as +1, 0, −1) factorial design for the 
optimization of two variables with 13 runs (5 centre points) was applied. Droplet size 
(Y1), transmittance (Y2), Zeta-potential (Y3), and PDI (Y4) were selected as responses. 
Experiments were run in random order to increase the predictability of the model. The 
modelling of corresponding response surfaces was carried out using second order models, 
which can describe the surface curvature with the following polynomial equation:  




where 𝑌 is the dependent variable; 𝑏0 the intercept is the arithmetic average of all quantity 
outcomes of 13 runs; 𝑥 are the independent variables (𝑥1 oil:Smix ratio, 𝑥2 emulgent:co-
emulgent ratio) and 𝑏 parameters mark the regression coefficients characterizing the main 




an optimization process is to find the most desirable set of conditions. Optimization of 
multiple responses was carried out by graphical optimization, which set minimum or 
maximum limits for each response then created an overlay graph highlighting an area of 
desired operability. The optimization and statistical experiments were designed and 
evaluated using the Design-Expert® software, version 7.0.0 (Stat-Ease® Inc., 
Minneapolis, MN, USA, 2005). In the doctoral thesis a 95% confidence interval and a 
corresponding 0.05 significance level was used. In all cases, when the p value was less 
than (or equal to) 0.05, then the null hypothesis was rejected and the result was regarded 
as statistically significant. 
3.5.6. Characterization of Optimized BSNEDDS  
3.5.6.1.Droplet size, Transmittance, PDI, and Zeta-Potential 
Measurements  
Droplet size, transmittance, and PDI were determined according to Section 3.5.2. Zeta-
potential was measured using the Zetasizer Nano ZS™ (Malvern Instruments Ltd., 
Malvern, UK) by diluting 0.1 mL of optimized BSNEDDS with 100 mL of distilled water. 
The evaluation was based on Laser Doppler Micro-electrophoresis using the 
Smoluchowski model. The selection of the attenuator level and the position of the optics 
was set automatically. The instrument was operated by automatic selection of voltage 
based on the measured conductivity of the sample. The analysis was carried out at 37.0 
◦C in clear, disposable folded-capillary zeta cells. Five measurements with minimum 10 
runs/sample were performed for each sample, the mean values ± SD (mV) are reported. 
3.5.6.2.Determination of the Thermodynamic Solubility of Baicalin in 
Optimized SNEDDS  
2 g of selected oil, emulgent, and co-emulgent were thermostated and homogenized (37 
◦C, approximately 500 rpm, 1 h) in optimized ratios by a heatable magnetic stirrer. An 
excess amount of pure baicalin was added to the best pre-concentrate in sealed vials. 
Henceforth, the investigation was fulfilled as detailed in Section 3.5.1.  
3.5.6.3.Cloudpoint Measurement 
 Cloudpoint is the temperature above which an aqueous solution of a water-soluble 




times and placed in a water bath where the temperature was increased gradually (1.0 
◦C/min). Cloudpoint was recorded as the temperature at which the diluted formulation 
turned cloudy (visual perception).  
3.5.6.4.Effect of Dilution on Droplet Size and PDI  
The optimized formulation was evaluated for robustness of dilution. The pre-concentrate 
was diluted to 50, 100, 500, and 1000 times by distilled water in 100 mL Erlenmeyer-
beakers with continuous stirring at 37 ± 1 ◦C. Distribution parameters were measured 
using the dynamic light scattering method as described above (Section 3.5.2.). 
3.5.6.5.Long-Term Physical Stability of Nanoemulsions  
0.2 mL of optimized BSNEDDS was dropped by automatic pipette into 100 mL distilled 
water at 37 ± 1 ◦C, with continuous stirring for 1 h at approximately 500 rpm (IKA RT-5 
power heatable magnetic stirrer). After several minutes of mild stirring, an intrinsic 
droplet size and PDI were measured by Zetasizer Nano ZS™ (for setting parameters see 
Section 3.5.2.). The Erlenmeyer flask with stopper was stored at room temperature and 
protected from direct sunlight until further investigation. Determinations were performed 
at 37.0 ◦C throughout the storage time (1 day, 3 days, 7 days, 14 days, 21 days, 28 days). 
3.5.6.6.Atomic Force Microscopy  
Sample Preparation for AFM Imaging  
The BSNEDDS preconcentrate was diluted 107 -fold with distilled water. Five µL of this 
emulsion was dropped on a freshly cleaved mica surface and was frozen by pouring 
approximately 30 mL liquid N2 onto it. The sample was immediately placed in the 
lyophilisation chamber (CoolSafe™ 110-04 freeze dryer, ScanVac, Lillerød, Denmark), 
pre-cooled to −60 ◦C, and lyophilized at the following parameters: 10 min freezing at −40 
◦C, then drying at 0.020 hPa vacuum chamber pressure for 18 h. The shelf temperature 
was set at 15 ◦C for 1 h, 20 ◦C for 1 h, 30 ◦C for 8 h, and 40 ◦C for 4 h. Freeze-dried 
samples were stored protected from light at ambient humidity at 25 ± 1 ◦C and examined 





AFM Imaging and Analysis  
Lyophilized samples were imaged in non-contact mode with a Cypher S instrument 
(Asylum Research, Santa Barbara, CA, USA) at 1–2 Hz line-scanning rate in air using a 
silicon cantilever (OMCL AC-160TS, Olympus, Tokyo, Japan) and oscillated at its 
resonance frequency (typically 300–320 kHz). Temperature during the measurements 
was 29 ± 1 ◦C. Images were analyzed by using the built-in algorithms of the AFM driving 
software (IgorPro, WaveMetrics Inc., Lake Oswego, USA). AFM amplitude-contrast 
images are shown in this paper. To determine height variations, height-contrast data were 
used. 
3.6.Preparation of self-nanoemulsifying matrix pellets (SNEMPs) 
SNEMPs were prepared by extrusion-spheronization method using MCC alone 
(BSNEDDS-MCC) or with the combination of isomalt, (BSNEDDS-MCCIsm). Two 
different formulas were created according to Table X.  
Table X. Composition of liquid BSNEDDS preconcentrate and two SNEMPs expressed 
in % (w/w) 
 
BSNEDDS BSNEDDS-MCC BSNEDDS-MCCIsm 
Baicalin 2.5 1.25 0.83 
Peceol™ 13.93 6.965 4.64 
Kolliphor® EL 55.71 27.855 18.57 
Transcutol® P 27.86 13.93 9.29 
MCC - 50 33.33 
Isomalt - - 33.33 
 
The batch size was 50 g in all cases. The powders were accurately weighed and blended 
in a mortar with a porcelain pestle for 10 minutes. BSNEDDS was added slowly to the 
powder with thorough mixing of the components until the liquid preconcentrate was 
completely adsorbed. For a successful process, 4 g demineralized water was added to the 
mass. The wet mass was extruded using a single-screw extruder with the rotation speed 




Process Solutions Ltd., England) equipped with standard die plate of 1 mm diameter and 
1 mm depth holes. The extrudates were then spheronized for 4 minutes at 1000 rpm in a 
105-mm radial plate spheronizer using a saw-toothed frictional plate (Locost Kft, 
Hungary). The pellets were stored in drying chamber at 40 °C until further analysis.  
3.7.Physical characterization of SNEMPs 
3.7.1. Flow properties  
The flowability of matrix pellets were evaluated by measuring the flow rate through an 
orifice and calculating the Carr’s index and Hausner ratio using the bulk and tapped 
density results.  
The flow rate of the pellets was recorded as the ratio of mass (g) to time (s) using standard 
ASTM glass funnel with an orifice diameter of 10 mm (n = 3). 50 g of pellets were 
weighed in and introduced into the funnel. The funnel was standing on a horizontal 
surface fixed to a holder and a piece of paper was placed under it by maintaining about 
10 cm gap between the paper and tip of the funnel. The time needed for flowing 50 g 
pellets through the oriface was recorded. 
Bulk and tapped density were obtained using STAV 2003 Stampfvolumeter 
(J.Engelsmann AG.,Germany) equipped with Omron HFCX-A4 counter. 50 g of pellets 
from each formulation were weighed in and introduced into the dry graduated 250-cm3 
cylinder (readable to 2 cm3). The bulk and tapped density were determined according to 
Ph.Eur.9.0. by the formula m/V0. Hausner ratio was calculated as the ratio of tapped 
density to bulk density, whereas Carr’s index was calculated as the difference between 
tapped density and bulk density divided by tapped density and expressed as percent. 
3.7.2. Friability 
For friability testing, 10 g of pellets were accurately weighed and introduced into the 
friabilator (Erweka TA3R, Erweka GmbH, Germany). A drum, with 100 mm internal 
radius, a depth of 35 mm and subject to minimum static build-up was used. The pellets 
were tumbled at each turn of the drum on 12 pieces of straight projections with sizes of 
35×35×3 mm. These 12 projections extend from the outer wall to the middle of the drum. 
The investigation took 10 minutes with the rotation speed of 20 rpm. Particles smaller 
than 0.20 mm were regarded as attrition and friability was calculated as the weight loss 




3.7.3. Shape analysis 
One hundred pellets were randomly chosen from each batch to be analyzed. The pellets 
were placed on nonshiny black surface serving as the background. The pellets were 
illuminated from the top using cold white coherent fibre optic light (20V/150W, 50/60 
HZ, 3200 K, 450.000 fc illumination intensity) of Volpi Intralux 5000-1 cold light source 
(Volpi, Switzerland). Photomicrographs of pellets were taken with a digital camera 
(Coolpix 4500, Nikon, Japan) linked to a stereomicroscope (SMZ 1000, Nikon, Japan). 
One pixel corresponds to 3.048 µm. The images produced were digitized and analyzed 
using the computer program Image Pro® Plus 4.5 (Media Cynerbetics, USA). In this 
study, the pellet size and shape were characterized by roundness, aspect ratio (AR) and 
Feretmax diameter. 
3.7.4. Residual water content 
The water content of the dried pellets was determined using a Karl Fischer titrator (787KF 
Titrino, Metrohm AG, Switzerland). Prior to the titration of the samples the water 
equivalency factor of Hydranal was determined using sodium tartarate (Hydranal-water 
standard, Sigma–Aldrich Chemie GmbH, Germany). The solvent was extra dry methanol, 
which was titrated with Karl Fischer reagent (Hydranal-composite-5) before the 
measurement. 120 mg of pellets were accurately weighed, dispersed (15 sec at 15.000 
rpm) and titrated with the reagent three individual measurements.  
3.8.Solid state characterization of SNEMPs 
3.8.1. FT-IR  
Physicochemical properties of pure baicalin, various carriers, physical mixtures, 
BSNEDDS-MCC and BSNEDDS-MCCIsm pellets were examined using Jasco FT/IR-
4200 spectrophotometer (Jasco Products Company, USA) which was equipped with Jasco 
ATR PRO470-H single reflection accessory. The measurements were performed in 
absorbance mode. The spectra were collected over a wavenumber range of 4000 and 
400 cm−1. After 50 scans at a resolution of 4 cm-1, the measurements were evaluated with 





3.8.2. Raman spectroscopy 
The above-mentioned samples were analyzed using dispersive Raman spectroscopy with 
proprietary fluorescence rejection equipped with CCD detector (Bravo Handheld Raman 
Raw Material Analyzer, Bruker Optics Inc., USA). The measurements were carried out 
at room temperature in 5 ml volumetric vials with screw-caps. The spectra were obtained 
in the range 3200-300 cm-1 with spectral resolution 10-12 cm-1. The laser excitation 
wavelength was 700-1100 nm (DUO LASER™). The analysis was assessed with OPUS 
7.8 spectroscopy software (Bruker Optics Inc., USA). 
3.9.In vitro dissolution study and reconstitution properties of SNEMPs 
Dissolution testing was performed using Hanson SR-8 Plus™ Dissolution Test Station 
(Hanson Research, USA) by paddles method (USP apparatus 2) with 50 rpm at 37 ± 0.2 
°C. The formulations were screened in 500 ml aqueous-based dissolution media at 
pH=1.2 (Ph.Eur.9) and pH=6.8 (Ph.Eur.9). Pure baicalin, liquid BSNEDDS, BSNEDD-
MCC and BSNEDDS-MCCIsm pellets were exposed to the media and at predetermined 
time-points, 5 ml of samples were withdrawn and filtered through 10 µm pore size 
membrane full flow filters from the media by Hanson AutoPlus Multifill collector 
(Hanson Research, USA). After every sampling, media replacement was accomplished 
with 5 ml of fresh buffer solution. Dissolution studies were completed three times and the 
cumulative drug release (%) ± SD was analysed by UV-Vis spectrophotometry at 279 nm 
against equivalent proportions of excipients as blanks. Withdrawn and filtered samples at 
120 minutes were characterized for droplet size and PDI as described for liquid 
BSNEDDS in Section 3.5.2. 24 hours visual observation was fulfilled for any 










4.1. Preformulation studies 
4.1.1. Determination of Thermodynamic Solubility by Saturation Shake-Flask 
Method  
Baicalin is a weak triprotic acid (pKa1: 4.21, pKa2: 8.56, pKa3: >14) with remarkable pH-
dependent solubility. The water solubility of baicalin was determined in distilled water 
(67.03 ± 1.60 µg/ml), which is in close agreement with literature data  (25). The difference 
could be explained by dissimilar sample preparation methods, in particular, equilibration 
time. In the highly acidic environment of stomach, the neutral form of baicalin is 
overwhelmingly dominant, so the measured solubility can be considered as the intrinsic 
solubility of baicalin (11.64 ± 0.44 µg/ml) at pH 1.2 SGF. As the pH increases, the 
ionization processes contribute significant solubility improvement (10504 ± 330 µg/ml) 
at pH 6.8 SIF, where baicalin exists decisively in monoanionic form ([H2B]
-: 98.0%). 
Significant solubilizing impact of FaSSGF (33.21 ± 0.72 µg/ml) was found to be 
correlated to compendial pH 1.2 SGF. The ~3-times increase in solubility can be 
explained by the presence of surface-active agents (lecithin, taurocholate) in FaSSGF. 
Surprisingly, FaSSIF did not live up to our expectations. Instead of a remarkable 
solubilizing effect, a minor decrease (8111 ± 472 µg/ml) of thermodynamic solubility 
was found correlated to compendial pH 6.8 SIF (Tbl. XI.). Similar results were observed 
in the case of weakly acidic furosemide and niflumic acid by Takács-Novák et al  (18). 
The solubility of acidic zafirlukast was also negatively influenced by interactions of bile 
salt and soy lecithin, whereas the amphiphilic molecules exhibited significant positive 
effect for the weak base carvedilol  (170). The phenomena could be explained by the fact 
that taurocholate and lecithin micelles possess net negative charge, thus an electrostatic 
repulsion exists between the solute anion and the micelle. In the case of neutral and 










Table XI. Thermodynamic solubility (µg/ml) of baicalin in various compendial and 
biorelevant media 
 
Medium AVG SD 
Aqua dest. 67.03 1.60 
pH=1.2 (SGF) 11.64 0.44 
pH=6.8 (SIF) 10504 330 
pH=1.6 (FaSSGF) 33.21 0.72 
pH=6.5 (FaSSIF) 8111 472 
 
4.1.2. Acid-base properties  
In baicalin there are 12 protons connected to carbon atoms, but in 1H NMR spectra 
only the singlets of H8 and H3 on ring A, and the doublet of the aromatic H2’,6’ protons 
can be easily assigned, while the other aromatic protons occur in complex spectrum of 
multiplets. The protons of the monosaccharide unit overlap with each other and with the 
signals of the antioxidant ascorbic acid. The suppression of the large water signal also 
interferes with the observation of certain NMR signals. Thus, during the NMR-pH 
titration we followed the above mentioned three chemical shift signal sets.   
Since protonation processes are instantaneous on the NMR chemical shift time scale, 
the observed chemical shift (
obsdδ ) of a certain nucleus can be expressed as a weighted 









where weighting factors are mole fractions that can be expressed in terms of stepwise 



























Combining and rearranging Eq. (6) and (7) yields Eq. (8) that can be directly fitted to the 


























The logarithms of the obtained protonation constants correspond to the negative 
logarithms of dissociation constants, namely pKa1=logK3, pKa2=logK2 and pKa3=logK1  
(17). 
The NMR-pH titration curves can be seen in Figure 13, while the obtained dissociation 
constants are summarized in Table XII. The titration curves show that each observed 
nucleus displays chemical shift changes upon dissociation of each acidic proton.   
The methyl ester of baicalin has no free carboxyl functional group, therefore two 
dissociation constants could be fitted only. The obtained pKa values are demonstrated in 
Table XII. 
 
Table XII. Acid dissociation constants of baicalin and its methyl ester 
 
Baicalin Baicalin methyl ester 
AVG SD AVG SD 
pKa1 4.21  0.02 8.78  0.05 
pKa2 8.56  0.03 > 14 - 



















Figure 13. NMR-pH titration curves of the H2’,6’ (arom d) and H8 and H3 protons of 
baicalin. Computer fits of Eq. (8) are shown in solid lines. 
 
The first acid dissociation constant (pKa1) obviously belongs to the carboxyl group of 
baicalin, because the methyl ester derivate (without a free carboxyl group) has no 
dissociation constant in the acidic region. Furthermore, two independent studies 
established that the UV spectrum of baicalin shows no profound absorption variation, just 
a slight increase in absorption intensity upon the increasing solubility of baicalin in less 
acidic solutions  (19, 171). The two phenolic hydroxyl groups on C5 and C6 on ring A 
would cause a marked bathochromic shift upon their deprotonation  (172).  
Thus, pKa2 of baicalin and the analogous pKa1 of baicalin methyl ester belongs to one 
kind of the phenolic hydroxyl groups. The second phenolic hydroxyl deprotonation takes 
place above pH 14, but the exact value of the pKa3 of baicalin (or the analogous pKa2 of 
its methyl ester) cannot be determined with sufficient certainty. Due to the reasons below: 
- the pH value of highly alkaline solutions can only be determined with indicator 
molecules, like 1-methylguanidine, but their chemical shift is also influenced by the 
changing ionic strength and solvation at these extreme pH values  (173).      
- the chemical shift of baicalin is also influenced by the changing ionic strength and 




- the rapid oxidation of baicalin above pH 13, even in the presence of a large excess 
of ascorbic acid, makes the observation of its signals very difficult and uncertain. 
The high pKa3 values (above pH 13) of other biologically active catechols, like dopamine 
and epinephrine can be determined only with uncertainty for similar reasons  (174). 
A UV-pH titration attempted to determine the pKa2 and pKa3 values of baicalin, and 
claimed the 7.6 and 10.1, respectively  (19). However, these results are highly dubious in 
light of the oxidizability of baicalin in alkaline solutions. Namely, the change in the UV-
spectra of baicalin is not only the result of protonation, but also that of the decomposition. 
With the help of ascorbic acid, we could prevent this oxidative process, and during NMR 
study we could also monitor the pH range where the molecule has remained intact. The 
stability issues of baicalin were evaluated in buffered aqueous solutions at different pHs 
(2.0, 3.0, 4.5, 6.8, 7.4 and 9.0) and temperatures (4, 25 and 40 °C). Acidic environment 
and low temperature were protective factors to preserve the integrity of baicalin  (30). 
The knowledge of pKa values allows the calculation of species distribution diagram 
of baicalin (Fig. 14/A). 
 
Figure 14. The species distribution diagram (A), and the lipophilicity profile of 
baicalin (B) 
The neutral form of baicalin (H3B) is dominant up to pH 4.21. The monoanionic form 
(H2B
-) reaches its maximum at the pH of blood (pH 7.40), with 93.5%. The dianionic 
form (HB2-) becomes the dominant one above pH 8.56, while the trianionic form (B3-) 
starts to appear only in extremely alkaline solutions that have little relevance to 




4.1.3. Distribution Coefficient Measurements by the Stir-Flask Method  
When more than one electrical species is present in solution, the observed ratio of 
concentrations in partition experiments is the distribution coefficient (D), which takes 
into account the intrinsic species-specific lipophilicity of the various electrical species 
present (Pi), and their mole fractions in the aqueous phase (xi). 
For baicalin, the pH-dependent distribution coefficient is the sum of four products: 
 
BHBHBHBHHBHBBBii(pH) 3322




where xi mole fractions are pH-dependent quantities, while Pi parameters are pH-
independent ones. The lipophilicity profile (the variation of log D as a function of the 
aqueous pH) of a drug is essential in understanding its pharmacokinetic behaviour  (175).   
The log D value of 1.28 (0.08) measured with a standardized 0.15 M HCl solution 
characterizes the log P value of the neutral form. In such acidic solutions it is the dominant 
species and exhibits obviously higher lipophilicity than the anionic forms. In a previous 
study the log P of baicalin was reported to be “1.27 (pH 7)”. It is not exactly clear what 
the authors meant by this, probably they calculated the log P of baicalin from a log D 
measured at pH 7  (19).  
However, our log D value of -1.22 (0.02) measured with a pH 7.40 phosphate buffer 
is a composite one, where contributions of both the neutral and the monoanionic forms 
are important and comparable. The relative concentration of the dianionic form is only 
6.5% here, and due to its obviously smaller partition coefficient it can be neglected at this 







The mole fraction data can be calculated similarly as shown in Eq. (7), thus the 
partition coefficient of the anionic form can be obtained. The log P value of the anion 




the neutral and the anionic form. For phenols the typical difference in the octanol/water 
system is around 3 log units, further verifying our results  (175). These partition 
coefficients allow the construction of the lipophilicity profile of baicalin, which can be 
seen in Figure 14/B. The broad black line is the overall lipophilicity profile of the 
molecule, the sum of the contributions of its two important species. The distribution 
coefficient becomes monotonically smaller as the pH is increased. The contribution of 
the neutral form is dominant up to pH 6.77, but at higher pH values the anionic form is 




























4.1.4. Crystal habit 
SEM displayed micro scaled plates with angular edges in case of baicalin crystal’s 
(Fig.15, Fig.16.). This physical property predicts poor flowability and processability. 
Anisotropy during compression may significantly affect negatively the overall 
mechanical properties of the compact  (176).  
 
Figure 15. SEM image of baicalin crystals (2000x magnification) 
 







4.1.5. Particle size analysis 
The particle size of pure baicalin followed a bimodal distribution characterized by an 
expressed peak between 0.5-100 μm and a mild second peak between 100-300 μm 
(Fig.17.). The average surface weighted mean particle size (D [3,2]) measured by laser 
diffraction was 4.99 ± 0.126 μm.  The d (0.1), d (0.5) and d (0.9) values were 1.821, 5.757 
and 23.223, respectively. This number indicates the diameter of a particle at which 10%, 
50% or 90% of the particles in the sample are smaller. SEM results are comparable with 
values obtained by laser diffraction method, both suggest a particle size on the bottom of 
µm scale (Section 4.1.4.). The particle size distribution of the drug substance may have 
significant effects on final drug product performance (e.g., dissolution, bioavailability, 
content uniformity, stability, etc.) and have impact on safety, efficacy, and quality of the 
drug product. If the particle size is critical, the International Conference on 
Harmonization (ICH) guideline Q6A provides guidance on when and how a particle size 
specification should be considered  (177).  
 
Figure 17. Particle size distribution of baicalin 
The Span is the measurement of the width of the distribution. The narrower the 





























Baicalin demonstrated a high Span value (3.718 ± 0.158) indicating a wide particle size 
distribution. In the scientific literature and regulatory guidelines there is no acceptance 
limit for Span.  
4.2.Baicalin-cyclodextrin inclusion complexation 
4.2.1. Phase solubility studies 
Phase solubility analysis can provide valuable information about changes in drug 
solubility when it interacts with different concentrations of CDs. Since the changes of 
physicochemical and biological properties of a drug are dependent on the stability 
constant of CD complexes, it is essential to determine this parameter accurately (178).  
The phase solubility profile of baicalin- α-cyclodextrin complex showed a typical BS-type 
solubility curve, where the initial ascending portion is followed by a plateau region and 
then a slight decrease in total baicalin solubility accompanied by precipitation of complex. 
Baicalin- β-, γ-, HP-β-, RAMEB-, SBE-β-CD complexes revealed a linear enhancement in 
solubility of baicalin upon addition of increasing amounts of CD (Fig. 18.). This indicates 
that the complexation belongs to the AL-type, assuming 1:1 binding stoichiometry. 5.47 
times solubility enhancement was demonstrated by γ-CD encapsulation (67.03 μg/mL vs. 
366.64 μg/mL) compared to solubility of baicalin in DW. In case of RAMEB, SBE-β-CD 
and HP-β-CD the solubility improvement was significant, but less expressed, 2.88-, 2.55-
, and 1.59 times, respectively. The inclusion complex of α-, and β-CD didn’t reveal 
significant solubility enhancement. Based on Equation (5), the apparent stability 















Table XIII. Apparent stability constants (K1:1) and types of phase solubility diagrams of 
baicalin-CD systems at 25 °C 
 
CD K1:1 Type 
α - BS 
β 70.1 AL 
γ 329.8 AL 
HP-β 76.2 AL 
RAMEB 240.9 AL 
SBE-β 102.9 AL 
 
The largest K1:1 was found in case of γ-CD (329.8 M
-1), that can well be explained by the 
fact that γ-CD is neutral and has wide internal cavity (8 glucopyranoside units). The order 
of stability constants was as follows: γ-CD > RAMEB-CD > SBE-β-CD > HP-β-CD > β-









4.2.2. Signal Assignment of Baicalin and Characterization of Baicalin-
Cyclodextrin Inclusion Complexes Using 1H NMR and 2D ROESY 
Experiments  
The NMR analysis of baicalin was carried out in DMSO-d6 for complete assignment and 
published data were completed and corrected  (179, 180) (Fig.19.). The 1H NMR 
chemical shifts are in δ ppm (DMSO-d6, 400 MHz): 13.50-12.12 (1H, brs, COOH); 12.60 
(1H, brs, C-5-OH); 8.70 (1H, brs, C-6-OH); 8.07 (2H, dm, J=7.4 Hz, H-2’,6’); 7.67-7.54 
(3H, m, H-3’,4’,5’); 7.05 (1H, s, H-8); 7.02 (1H, s, H-3); 6.05-4.65 (1H, brs, C-4”-OH); 
5.53 (1H, d, J=3.9 Hz, C-2”-OH); 5.34 (1H, d, J=3.7 Hz, C-3”-OH); 5.25 (1H, d, J=7.4 
Hz, H-1”); 4.08 (1H, d, J=9.5 Hz, H-5”); 3.52-3.26 (3H; m; H-2”,3”,4”). 13C NMR data 
in δ ppm (DMSO-d6, 100 MHz): 182.6 (C-4); 170.1 (C-6”); 163.6 (C-2); 151.3 (C-7); 
149.2 (C-9); 146.8 (C-5); 132.1 (C-4’); 130.9 (C-1’); 130.6 (C-6); 129.2 (C-3’,5’); 126.4 
(C-2’,6’); 106.1 (C-10); 104.8 (C-3); 99.9 (C-1”); 93.7 (C-8); 75.5 (C-5”); 75.3 (C-3”); 
72.8 (C-2”); 71.3 (C-4”).  
 
 
Figure 19. Total signal assignment of baicalin and numbering of the molecule (blue 
values: 1H NMR chemical shifts, red values: 13C NMR chemical shifts; in δ ppm; 
400/100 MHz; 25°C) 
To obtain direct evidences for the interaction between baicalin and CDs, ROESY 
experiments were also carried out. In the case of γ-CD unequivocal interaction was seen 
for H-3 protons of the CDs and aromatic protons (H-2’,4’ and H-3’,5’) of baicalin 
(Fig.20.). Weaker, but appreciable cross-peaks were shown also for H-5 protons of γ-CD 
with the aromatic protons (H-2’,4’ and H-3’,5’) and between H-3 of γ-CD and H-3 of 




For RAMEB-CD cross-peaks between the same moieties were found but at lower 
intensity (Fig.21.). The baicalin-SBE-β-CD complex gave only the H-3 (baicalin) – H-3 
(CD) interaction near to the noise (Fig.22.). 
 
Figure 20. 2D ROESY NMR spectrum of Baicalin-γ-CD complex; 400 MHz; 25 °C 
 






Figure 22. 2D ROESY NMR spectrum of Baicalin-SBE-β-CD complex; 
400 MHz; 25°C 
Proton chemical shifts in 1D 1H NMR spectra also differ before and after forming 
inclusion complexes (Tbl. XIV., Fig. 23.). All protons of the A, B and C rings were 
affected by the interaction with CDs. Most promoted chemical shift change was found 
for the γ-CD complex: ca. 0.1 ppm for H-3 and H-2’,6’; ca. 0.06 ppm for H-8 and H-
3’,4’,5’. In case of SBE-β and RAMEB-CD inclusion complexes the chemical shift 
changes were in the range of 0.01-0.02 ppm. 
 
Figure 23. 1H NMR spectra of baicalin (blue), baicalin-𝛾-CD (red), baicalin-RAMEB-




Most clear evidences about complexation could be gained from the sample with γ-CD. 
ROESY and 1H NMR results suggest that H-2’,6’ and H-3 are inserted into the cavity, 
because these protons underwent the largest chemical shift change in 1H spectrum, and 
NOE interactions could also be developed with H-3 of CD. H-3’,4’,5’ show also NOE 
correlation with H-3 of CD, but a decreased chemical shift change could be detected, thus 
these protons are in the cavity, but near the rim of the CD and became not significantly 
shielded. Since aromatic protons have more intensive through-space interaction with H-
3 of CD, than H-5 protons, it could be concluded, that the aromatic moiety is closer to the 
wide rim. Concerning the complexation with RAMEB-CD, analogous interactions could 
be observed as in case of solution with γ-CD, but weaker NOE interactions and moderate 
chemical shift changes could be observed. The results for baicalin-SBE-β-CD suggest 
only weak interaction between baicalin and the CD. 
 
Table XIV.1H NMR chemical shifts of baicalin in its solution and inclusion complexes; 
400 MHz; 25 °C 
 





 (ppm)  (ppm)  (ppm)  (ppm)  (ppm)  (ppm) 
 
(ppm) 
H-3 6.9331 6.8348 -0.0983 6.9145 -0.0186 6.9211 
-
0.0120 




























4.2.3. Molecular Modelling of the Binding into Cyclodextrin  
In the structures of CD, three different hydroxyl groups can be distinguished, two at the 
upper ring, and one at the bottom ring for each hexose unit. According to computational 
study at B3LYP/6-31G(d) level of theory, anionic baicalin molecule docks and 
accommodates differently into the -CD and -CD. In the most preferred arrangement of 
the baicalin in -CD, it breaks one of the weak hydrogen bonds (HB) of Type-I OH at the 
upper ring and forms a strong HB (Bonding-A) with the carboxylate group of baicalin on 
ring-III, as illustrated in Figure 24. The carbonyl group on the ring-I also forms a weak 
interaction with a neighbouring C–H of the opposite hexose.  
 
 
Figure 24. Different bonding types between baicalin and β-, γ-CDs. For β -CD, the 
bonding pattern consists of Bonding-A and Bonding-B, while for γ-CD it is Bonding-A 
and Bonding-C obtained by B3LYP/6-31G(d) level of theory. 
The bonding pattern is different with -CD. Beside the same Bonding-A, the carbonyl 




site (Bonding-C). This difference can be revealed in their bonding energy values, listed 
in Table XV. The calculated complexation energy in vacuum is –162.4 kJ mol–1 for -CD, 
while it is significantly stronger for -CD (–181.5 kJ mol–1), exhibiting 19.1 kJ mol–1 
beneficial energy difference in favour of -CD. This bonding pattern difference can be 
explained in terms of the diameter, related to the respective 7 and 8 glucose units in - and 
-CD cyclodextrins. The strongest interaction is forming between the carboxylate and one 
of the OH groups of CD (Bonding-A), making a strong and rigid anchor. In the case of 
even number (n = 8; -CD), the opposite site provides beneficial OH group for the baicalin 
carbonyl (Bonding-C), while for odd number (n = 7; -CD), the opposing wall can offer 
only a C–H group (Bonding-B). 
 
Table XV. Energy differences of the complexation process of the four types of 
cyclodextrins (-CD, -CD, RAMEB-CD and SBE--CD) obtained by B3LYP/6-
31G(d) level of theory 
 
Complexation energy 
(E; kJ mol–1) 
E; kJ mol–1 
relative to -CD 
-CD –162.4 0.0 
-CD –181.5 –19.1 
RAMEB-CD –164.2 –1.8 
SBE--CD –41.0 +121.4 
 
To model the partially methylated cyclodextrin, we constructed the model of 
RAMEB-CD according to literature data  (181). Here, the seven hydroxyl groups (OH; 
Type-III) at the bottom ring are completely methylated, while five out of the total of 14 
the OH groups (Type-I and II) are methylated at the upper ring randomly. As Figure 25 
illustrates, the original cone shape of the -CD has significantly changed by the partial 
methylation. Namely, the narrower bottom ring of the -CD became extended and forms 
a loose ring structure. It makes significantly larger room to accommodate of the baicalin 
molecule. However, the RAMEB-CD still provides enough hydroxyl groups at the upper 
ring to form strong hydrogen bonding (Bonding-A), like the original -CD, as illustrated 
in Figure 25. The apolar bottom part of the CD can interact more comfortably with the 
phenyl substituent of the drug molecule. The computed complexation energy is little bit 






Figure 25. Shapes of the two modified β-cyclodextrins (RAMEB-CD and SBE-β-CD), 
obtained by B3LYP/6-31G(d) level of theory. On the right-hand side structures 
represent the different bonding patterns between baicalin and modified β-CD. RAMEB-
CD and SBE-β -CD consist of Bonding-A + Bonding-B, and Bonding-B + Bonding-D 
 
The seven sulfobutylether groups in SBE-β-CD typically replace the seven Type-III OH 
groups. Supposing a complete deprotonation of the sulfonic acid, the seven anionic 
sulfonate groups expand the cyclodextrin ring extremely, due to the Coulomb repulsion 
of the anions. This effect opens the bottom end of the CD and closes the upper ring. 
During the complexation, the neutral form of baicalin needs to re-open the upper ring to 
get into the hole and forms a similar HB with one of the Type-I OH, but here the COOH 
points to the CD-OH (Bonding-D). The computed energy is far less beneficial, than that 
of for -CD, which should not be realistic, compared to the experimental result. Here, the 
neglect of the whole solvent environment overestimates the coulomb repulsion, which 
lowers the level of reliability. The calculated complexation energies refer to vacuum, 
while in case of phase-solubility and NMR studies a complex solvent system was utilized. 





Figure 26. Optimized structures of various cyclodextrins and their complexed forms at 
B3LYP/6-31G(d) level of theory 
 
4.3.Liquid Self-nanoemulsifying Drug Delivery Systems 
4.3.1. Solubility Studies  
Oil represents one of the most important excipients in SNEDDS formulations. To achieve 
optimal drug loading, it is essential to choose the oil having greatest solubilizing capacity  
(182). Amongst the various oils that were examined, Peceol™ showed significantly the 
highest solubilizing capacity (719.1 ± 83.05 µg/ml) for baicalin followed by Labrafac™ 
Lipophile WL 1349 and Maisine® CC. The investigated natural oils were unsuitable to 




Based on solubility studies, Peceol™ was the ideal choice as oily phase. Selection of 
surfactant depends on several factors such as solubilizing capacity for the API, the 
efficiency and rapidity to emulsify the oil and safety  (106). Non-ionic surfactants are 
considered less toxic than ionic ones. Due to these considerations we analyzed five non-
ionic surfactants with various HLB values. The highest solubility of baicalin was obtained 
in Labrasol® (3609.4 ± 277.39 µg/ml) followed by Kolliphor® EL and Labrafil® M 1944 
CS. Solubility studies are necessary, but not sufficient conditions for selecting an 
emulgent, so Kolliphor® EL, Labrafil® M 1944 CS and Labrasol® were tested further for 
emulsification ability (see Section 4.3.2.)  (184). The role of the co-surfactant together 
with the surfactant is to lower the interfacial tension, and to facilitate dissolving large 
amount of API in the oily phase  (182). Drug absorption and dispersibility can be also 
improved by prudent selection of co-emulgent  (82). Transcutol® P, an ether derivate 
revealed extreme high (13742.5 ± 691.74 µg/ml) solubilizing capacity, and were chosen 
therefore as co-surfactant for further investigations. The results of solubility study are 
presented in Figure 27.  
 
Figure 27. Thermodynamic solubility of baicalin in various oils (red), emulgents (blue), 








4.3.2. Screening of Surfactants for Emulsifying Ability  
Three emulgents with various molecular structure and HLB-value were chosen to screen 
their ability to emulsify the oily phase by droplet size (Fig.28/A) and turbidity analysis 
(Fig.28/B). The droplet size of emulsions of Labrasol® and Kolliphor® EL demonstrated 
reduction with increased emulgent content, while Labrafil® M 1944 CS did not indicate 
any significant droplet size shift mixed with various oil ratios. All Labrasol® containing 
formulations proved unacceptable self-emulsification efficiency and turbid systems were 
generated. Kolliphor® EL showed the best emulsification ability and produced the most 
desired droplets with 151 ± 1.2871 nm. Turbidity analysis revealed a clear augmentation 
of transmittance with increased oil:emulgent ratios for Kolliphor® EL and Labrasol®, 
however Labrafil® M 1944 CS expressed a sharp decline. It has been reported, that the 
required HLB value to form o/w nanoemulsion is greater than 10  (185). The very poor 
emulsifying ability of Labrafil® M 1944 CS can be attributed to its low HLB-value 
(HLB=3). Labrasol® (HLB=14) exhibited better affinity for the oil phase compared to 
Labrafil® M 1944 CS, although the best compatibility was shown with Kolliphor® EL 
(HLB=12). This indicates that nanoemulsification was also influenced by other factors 
besides of HLB value, such as the chemical structure, saturation and chain length of 














We have selected Kolliphor® EL giving the greatest transmittance and lowest droplet size 
with increased oil:emulgent ratios. In consideration of the aforementioned results and 
observations, we can conclude that Peceol™, Kolliphor® EL and Transcutol® P is the best 
choice for designing baicalin containing SNEDDS. 
 
Figure 28. Emulsification ability of Kolliphor® EL (blue), Labrafil® M 1944 CS (red) 
and Labrasol® (yellow) with Peceol™ at different w/w ratios characterized by droplet 















4.3.3. Construction of Ternary Phase Diagram  
The ternary phase diagram of different formulations of SNEDDS prepared by varying the 
concentration of Peceol™, Kolliphor® EL and Transcutol® P is demonstrated in Figure 
29. The ternary phase diagram was constructed based on solubility and emulsification 
studies to identify the nanoemulsifying region (Z-avg < 200 nm, T% > 90%), and the 
composition also helps to determine the concentration range of components for the 
formation of a nanoemulsion. Compositions containing more than 22% oil phase were 
found to be out of nanoemulsifying region. It was observed, that at least 40% surfactant 
is required for producing droplets under 200 nm.  
 
Figure 29. Ternary phase diagram of Peceol™, Kolliphor® EL and Transcutol® P based 
on droplet size and transmittance analysis. The area bordered by grey squares represents 
the self-nanoemulsifying region. (n=3) 
4.3.4. Optimization of SNEDDS Preconcentrates  
Independent variables and their levels and dependent variables with goals used in 
Face-centered experimental design is indicated in Table XVI. Thirteen experiments were 
designed to understand the influence of formulation variables (oil:Smix and emulgent:co-
emulgent ratios) affecting droplet size, transmittance, Zeta-potential and PDI (Tbl. XVII). 
The values of responses Y1 (Z-avg (nm)), Y2 (Transmittance (%)), Y3 (Zeta-potential 
(mV)) and Y4 (PDI) ranged from 20.3 to 200.8 nm, 78.7 to 100%, -33.8 to -15.9 and 0.25 
to 0.69, respectively. The ratio of maximum to minimum for responses Y1, Y2, Y3 and 




not required for these responses, no aliases were found for Quadratic model, and in all 
cases the Sequential Model Sum of Squares detected the Quadratic model as significant. 
The models were validated by one-way analysis of variance (ANOVA), lack of fit and R2 
tests. The Model F values for responses Y1, Y2, Y3, and Y4 were 120.36, 66.24, 50.03, 
and 47.72, respectively, which implied that models were significant. The final polynomial 
equations and a summary of the regression analysis on all the responses are presented in 
Tab. XVIII. The main effects (b1, b2) represent the average result of changing one variable 
at a time from its low level to its high level while the other is kept fixed. The interaction 
term (𝑏12) show how Y1-Y4 change when two variables are simultaneously changed, 
while the quadratic terms (b11, b22) symbolize nonlinearity. The positive sign of the 
coefficients indicates synergistic effect on responses, while the negative sign expresses 
antagonistic effect. Our analysis also revealed non-significant lack of fit test results 
(p>0.05) for all the measured responses, which strengthened the reliability of the models. 
Table XVI. Independent variables and their levels (A) and dependent variables with 
goals (B) used in Face-centered experimental design 
A)  Levels 
Independent variables Symbol -1 0 +1 
Oil:Smix ratio X1 1:8 1:6 1:4 
Emulgent:co-emulgent 
ratio 
X2 1:1 2:1 3:1 
 
B) 
Dependent variables Symbol Goal 
Z-avg (nm) Y1 Y1 <200 nm 
Transmittance (%) Y2 Y2 >90% 
Zeta-potential (mV) Y3 Y3 >±20 mV 























10 1 0 0 99.5 96.7 -27.4 0.46 
7 2 0 -1 138.4  97.7 -22.1  0.48 
1 3 -1 -1 27.7  99.9  -17.8  0.28  
8 4 0 1 84.4  97.5 -33.8  0.54 
12 5 0 0 94.1  96  -28.6  0.49  
4 6 1 1 136.2  88.6  -25.5 0.69  
3 7 -1 1 20.3  100  -25.7  0.25  
9 8 0 0 95.5  97.8 -27.7  0.46  
2 9 1 -1 200.8 78.7  -15.9  0.54  
6 10 1 0 141.3 82.6  -19.1  0.59  
13 11 0 0 98.9 96.8  -27.1  0.41 
5 12 -1 0 23.7 100  -23.3  0.27  
11 13 0 0 97.9 96.1 -27 0.44 
 
Analysis of standardized main effects (only significant values p <0.05 are discussed) 
showed that droplet size (Y1) was affected by synergistic effect of oil:Smix ratio, 
antagonistically influenced by emulgent:co-emulgent ratio, interaction term between 
oil:Smix and emulgent:co-emulgent ratio, and quadratic terms of oil:Smix ratio. 
Transmittance (Y2) was synergistically affected by emulgent:co-emulgent ratio and 
interaction between oil:Smix and emulgent:co-emulgent ratio, and an antagonistic effect 
was found with oil:Smix ratio. In the case of Zeta-potential (Y3) we found a positive 
correlation with oil:Smix ratio and its quadratic term, and a negative correlation with 
emulgent:co-emulgent ratio. PDI (Y4) showed significant synergistic effect with oil:Smix 
ratio and emulgent:co-emulgent ratio. Based on these results, it is obvious, that all the 





Table XVIII. Summary of results of regression analysis for responses Z-avg, 
Transmittance, Zeta-potential and PDI with R2, Adj-R2 and Pred-R2 tests. (statistical 
significance indicated by * (p <0.05)) 






b0 + 97.24 + 96.74 - 27.61 + 0.46 
b1 + 67.77* - 8.33* + 1.05* + 0.17* 
b2 - 21.00* + 1.63* - 4.87* + 0.030* 
b12 - 14.30* + 2.45* - 0.43 + 0.045* 
b11 - 14.91* - 5.58 + 6.54* - 0.045 
b22 + 13.99 + 0.72 - 0.21 + 0.035 
R2 0.9885 0.9793 0.9728 0.9730 
Adj-R2 0.9803 0.9645 0.9533 0.9537 
Pred-R2 0.8887 0.8222 0.7732 0.9047 
 
Analysis of standardized main effects (only significant values p <0.05 are discussed) 
showed that droplet size (Y1) was affected by synergistic effect of oil:Smix ratio, 
antagonistically influenced by emulgent:co-emulgent ratio, interaction term between 
oil:Smix and emulgent:co-emulgent ratio, and quadratic terms of oil:Smix ratio. 
Transmittance (Y2) was synergistically affected by emulgent:co-emulgent ratio and 
interaction between oil:Smix and emulgent:co-emulgent ratio, and an antagonistic effect 
was found with oil:Smix ratio. In the case of Zeta-potential (Y3) we found a positive 
correlation with oil:Smix ratio and its quadratic term, and a negative correlation with 
emulgent:co-emulgent ratio. PDI (Y4) showed significant synergistic effect with oil:Smix 
ratio and emulgent:co-emulgent ratio. Based on these results, it is obvious, that all the 
factors contribute in determining the characteristics of SNEDDS.  
Response surface method (RSM) designs help to quantify the relationships between one 
or more measured responses and the vital input factors. The generated 3D plots show how 
any of two factors affects the response. Figure 30/A, displays the effect of oil:Smix (X1), 
emulgent:co-emulgent (X2) and their interaction on droplet size (Y1). When both oil:Smix 





By increasing oil content while keeping X2 at 1:1, droplet size was risen to 200.8 ± 1.64 
nm. As the amount of surfactant and co-surfactant mixture increases, so decreases the 
droplet size. It can be attributed by the fact, that the strong localization of surface-active 
agents at the oil–water interface reduces the interfacial free energy. The higher the oil 
content, the more extensive the total interfacial area to be stabilized, and the amount of 
surfactant molecules are not sufficient to cover the oil droplets and lower interfacial 
tension at o/w interface. The lowest droplet size (20.3 ± 0.08) was achieved at low oil:Smix 
level (1:8) and at high emulgent:co-emulgent ratio (3:1). The 3D response surface plot of 
transmittance is demonstrated in Figure 30/B.  
 
Figure 30. 3-D response surface plots for effect of oil:Smix ratio and emulgent:co-
emulgent ratio on Z-avg (A), Transmittance (B), Zeta-potential (C) and PDI (D). 
Overlay plot (E) for various oil:Smix and emulgent:co-emulgent ratios, where the area 
that satisfies the constraints is yellow, while the area that does not meet criteria is grey. 
A) 
 





















Formulations are considered transparent if the percentage transmittance is above 90%, 
which is due to the fact that droplet size is not larger than 25% of the wavelength of 
incident light  (187). Lower oil:Smix ratios were favourable for producing -irrespective to 
the emulgent:co-emulgent ratio- perfectly transparent nanoemulsions (100% and 99.9%). 
As the amount of oil decreases in the formulation, the transmittance increases and vice 
versa. Examining the responses, the minimum transmittance value (78.7 ± 0.08%) was 
detected at high level of oil:Smix and at low level of emulgent:co-emulgent. Figure 30/C 
illustrates the relationship between oil:Smix and emulgent:co-emulgent ratios on Zeta-
potential. The lowest Zeta-potential (-33.8 ± 0.83 mV) was observed at middle level of 
oil:Smix and high level of emulgent:co-emulgent ratio. This electrokinetic potential was 
decreased by decreasing the ratio of co-surfactant. This phenomena might be explained 
by the insufficient co-surfactant concentration, because the co-surfactant plays a special 
role in reduction of interfacial tension and providing flexibility of the interfacial film  
(182). The highest Zeta-potential (-15.9 ± 0.72) was detected at high oil:Smix and low 
emulgent:co-emulgent level. This result –besides the low Transcutol® P concentration- 
can be explained by the chemical structure of Peceol™. The oil composed of carboxyl 
groups of fatty acids, and in solutions it can be deprotonate to carboxylate anions  (188). 
The analysis of PDI (Fig.30/D) pointed out parallel relationships with the droplet size 
measurements and also supplementing some differences as well. Emulgent:co-emulgent 
ratio influenced slightly the polydispersity indices, while effect of various oil:Smix ratios 
were significant on PDI. The narrowest droplet size distribution was 0.25 and found when 
oil:Smix was at low level and emulgent:co-emulgent was high. We can conclude, that 
higher oil content of the preconcentrate produces nanoemulsion with wider droplet size 
distribution. The desired PDI value should be less than 0.400, which implies a uniform 
particle size distribution (189). 
All the measured responses were graphically optimized using the optimization module of 
the software. With multiple responses it is necessary to find regions where requirements 
simultaneously meet the critical properties. By superimposing or overlaying critical 
response contours on a contour plot it is possible to visually search for the best 
compromise. The minimum and maximum acceptable responses were determined 
according to the scientific literature: droplet size <200 nm, transmittance >90%, Zeta-




We selected our optimized formulation from the middle of the yellow labelled area of the 
overlay plot. The optimized SNEDDS contains Peceol™ (14.29%, w/w), Kolliphor® EL 
(57.14%, w/w) and Transcutol® P (28.57%, w/w). The predicted values for responses Y1, 
Y2, Y3 and Y4 were 59.63 nm, 99.51%, -26.50 mV and 0.36, respectively. Three batches 
of the optimized formulation were prepared and measured 52.87 ± 0.5322 nm, 99.87 ± 
0.18%, -25.42 ± 0.710 mV and 0.335 ± 0.004. The predicted and observed values of 
responses were in very close correlation, indicating the reproducibility of the model. 
4.3.5. Characterization of Optimized BSNEDDS  
4.3.5.1.Droplet size, Transmittance, PDI, and Zeta-Potential 
Measurements  
The droplet size, transmittance, PDI and Zeta-potential of optimized BSNEDDS was 
measured. It is well-known fact, that droplet size is an essential feature, and can 
significantly influence the in vivo fate of a nanoemulsion. The globule size of emulsion 
also determines the rate and extent of drug release  (190). The Z-avg was highly desirable 
with 86.75 ± 0.3553 nm, likewise PDI value with 0.403 ± 0.007, indicating that the system 
had narrow droplet size distribution and anticipating an improved drug release. 
Transmittance of diluted sample was 99.93 ± 0.13%. In general, when the Zeta-potential 
of an emulsion is high (> ± 20 mV), the repulsive forces exceed the attractive forces, 
resulting in a relatively stable system. The long-term stability of a nanoemulsified system 
can be estimated by examine the fluctuation of Zeta-potential  (191). The Zeta-potential 
of optimized BSNEDDS was -24.3 ± 1.44 mV and the specific conductivity was found to 
be 0.0135 ± 0.002 mS/cm.  
4.3.5.2.Determination of the Thermodynamic Solubility of Baicalin in 
Optimized SNEDDS  
The thermodynamic solubility of baicalin in optimized SNEDDS was 2714.3 ± 113.8 
µg/ml. It indicates 40.5-times solubility improvement correlate with solubility in distilled 








A special property of non-ionic surfactants is cloudpoint, the temperature above which 
the surfactant phase separates and precipitates out of solution. The cloudpoint is higher 
than 37 °C in ideal case because of the risk of irreversible phase separation in the body  
(104). The cloud point for BSNEDDS was 71-73 °C providing stabile nanoemulsion in 
vivo at physiological temperature.  
4.3.5.4.Effect of Dilution on Droplet Size and PDI  
After oral administration of SNEDDS, nanoemulsion formation upon dilution takes place 
in vivo. It is relevant aspect to demonstrate that uniform nanoemulsions are formed in 
terms of various dilutions and these nanoemulsified systems do not show any sign of 
phase separation and/or precipitation. The drug may precipitate in vivo at higher dilutions 
which might significantly affect drug absorption  (192). All emulsions were found to be 
in the acceptable nanoemulsion region (Z-avg <200 nm, T >90%, PDI <0.4), proving their 
robustness to dilution. After 24 hours of inspection, neither phase separation, nor 
precipitation was observed. In vitro results showed that BSNEDDS upon different 
dilutions forms uniform nanoemulsions and drug solubility in BSNEDDS was adequate 
(no precipitation). 
4.3.5.5.Long-Term Physical Stability of Nanoemulsions  
The long-term physical stability of BSNEDDS was evaluated by droplet size, PDI 
measurements and macroscopic observation for a month. Various physicochemical 
phenomena can lead to the breakdown of a nanoemulsion (e.g. creaming, flocculation, 
Ostwald ripening), but these undesirable mechanisms can be identified. There was no 
significant change in droplet size and/or PDI over the investigated period comparing to 
initial values. The visual observation revealed no phase separation, creaming or 
precipitation. The O/W baicalin containing nanoemulsion demonstrated high physical 






Table XIX. Results of long-term stability analysis of liquid BSNEDDS formula 
 (Mean ± SD; n=3) 
Storage intervals 
(days) 
Z-avg (nm)  PDI  
0 81.24 ± 0.17 0.406 ± 0.007 
1 80.14 ± 0.08 0.405 ± 0.006 
5 79.23 ± 0.14 0.379 ± 0.002 
7 82.37 ± 0.10 0.400 ± 0.002 
21 79.53 ± 0.05 0.443 ± 0.003 
28 80.86 ± 0.28 0.3890.003 
 
4.3.5.6. Atomic Force Microscopy   
Lyophilized nanodroplets dispersed homogeneously on mica surface showing no signs of 
aggregation (Fig.31/A). They appeared as circular objects with smooth surface and 
rounded topography (Fig.31/B), which corresponds well to what one would expect from 
a surface adsorbed droplet. Height of particles followed a slightly right skewed 
distribution (Fig.31/C). Lack of outstandingly large particle sizes indicate that droplets 
did not coalesce during sample preparation. Mean height of droplets (±SD) was 15.4 ± 
9.0 nm what was lower than the diameter (52.87 ± 0.5322 nm) obtained from DLS data. 
This may stem from two factors: (1) Flattening of emulsion droplets on mica surface, or 
(2) the fact that DLS yields the hydrodynamic size of the droplets, which is bigger than 
the real particle diameter. [Since the diameter of surface adsorbed droplets is about two 
times larger than their height (Fig.32/A) at first sight one would think there was a 
considerable flattening indeed. However, tip convolution artefact on its own can result in 
this extent of artefactual apparent widening of vesicle diameter being the tip radius 





Figure 31. AFM amplitude-contrast images of surface absorbed lyophilized oil droplets 
(A). Area marked by dashed line is shown in (B). (C) Height distribution of droplets 
(n=122). 
To estimate the diameter of the original, fluid phase emulsion droplets, volume of surface-
adsorbed droplets was determined. From this, the real diameter of fluid phase droplets 
could be calculated, assuming that they have spherical shape and there is no volume 
change upon surface-adsorption. Estimated fluid phase droplet radius showed an apparent 
normal distribution with 23.6 ± 12.0 nm as mean ± SD (Fig.32/B). This value falls 
somewhat closer to the DLS size, the difference between them might be attributed to the 
hydrodynamic overestimation of particle size by the DLS method. 
 
Figure 32. Correlation between the height and diameter of surface-adsorbed oil droplets 
(A). Histogram of estimated radius of oil droplets in fluid phase (B). Estimation based 




4.4.Physical characterization of SNEMPs 
4.4.1. Flow properties  
The flowability of pellets were evaluated by different methods in order to characterize 
the formulation for this property as precisely as possible. Flow properties of pellets are of 
primary importance for precise dosing in case of capsules and tablets, mixing and 
handling processes. The flow through an orifice showed that BSNEDDS-MCC and 
BSNEDDS-MCCIsm formulations have similar and excellent flow properties. Carr’s 
index calculated from bulk and tapped density values ranged from 6.81% to 8.33%, while 
Hausner-ratio ranged from 1.16 to 1.19 for BSNEDDS-MCCIsm and BSNEDDS, 
respectively. These values indicate excellent flow characteristics and low interparticle 
interactions of the investigated formulations. We can conclude that in the case of baicalin 
containing matrix pellets the addition of isomalt slightly improves the flowability. The 
summary of flow properties can be seen in Table XIX. 
4.4.2. Friability 
Pellets with good physical properties have low friability. It is a convenient factor to 
predict pellet behaviour during film coating, compressing, capsule filling and packaging. 
The friability of BSNEDDS-MCCIsm and BSNEDDS-MCC was 0.042% and 0.045%, 
respectively (Tbl. XIX.). There aren’t any standardized methods in Ph.Eur.9. for testing 
friability of pellets, consequently there is no official acceptance limit value. The 












4.4.3. Shape analysis 
The roundness and AR are informative shape parameters, while the maximum Feret 
diameter can be used to demonstrate the mean particle size of pellets (193). The upper 
limit for aspect ratio is 1.20, roundness close to 1 expresses an ideal sphere as was 
previously reported  (194). The average value of AR was 1.12 for BSNEDDS-MCCIsm 
and 1.11 for BSNEDD-MCC, whereas the average roundness was 0.90 and 0.91, 
respectively. The results of shape parameters of matrix pellets indicated spherical 
structure. Table XX. demonstrates the size and shape analysis of various spheres. 
Representative stereomicroscopic pictures of different pellet formulations can be seen in 
Figure 33.  
Table XX. Summary of physical characterization of BSNEDDS-MCCIsm and 
BSNEDDS-MCC matrix pellets (Mean ± SD; n=3) 
 BSNEDDS- MCCIsm BSNEDDS-MCC 
Bulk density (g/cm
3
) 0.45 ± 0.007 0.61 ± 0.009 
Tapped density (g/cm
3
) 0.48 ± 0.008 0.67 ± 0.011 
Carr's index (%) 6.81 ± 0.14 8.33 ± 0.17 
Hausner-ratio 1.16 ± 0.107 1.19 ± 0.11 
Flowability (g/s) 6.02 ± 0.205 6.88 ± 0.213  
Friability (%)  0.042 ± 0.35 0.045 ± 0.21 
Res. water content (%) 3.947 ± 0.104 2.586 ± 0.251 
Feret
max
 (mm) 1.49 ± 0.072 1.33 ± 0.067 
AR 1.12 ± 0.08 1.11 ± 0.06 
Roundness 0.90 ± 0.07 0.91 ± 0.05 
 
 
Figure 33. Morphological characteristics of BSNEDDS-MCCIsm (A), 




4.4.4. Residual water content 
It was pointed out that the differences in the residual water content of the two formulations 
was slight, indicating that the drying process of BSNEDDS-MCCIsm/BSNEDDS-MCC 
spheres efficiently removed the free water added during the initial wet massing stage, in 
spite of the various amount of added water during the preparation step of pellets. Residual 
water content determined by Karl Fischer titration method was in case of BSNEDDS-
MCCIsm 3.947 ± 0.104%, while for BSNEDDS-MCC 2.586 ± 0.251% was registered.  
 
4.5.Solid state characterization of SNEMPs 
4.5.1. FT-IR 
The changes in crystallinity and the alteration of intermolecular (drug-excipient, 
excipient-excipient) interactions can be detected by Fourier-transformed infrared 
spectroscopy  (195). FT-IR spectra of baicalin, MCCIsm, MCC, BSNEDDS-MCCIsm 
and BSNEDDS-MCC pellets are shown in Figure 34. The following characteristic peaks 
were identified for pure baicalin: phenolic –OH group at 3491 and 3552 cm-1, -OH at 
3373 cm-1, -COOH at 1726 cm-1, C=C of phenyl at 1608, 1573 and 1498 cm-1, carbonyl 
C=O at 1656 cm-1 and C-O-C of ether at 1065 cm-1. Examining the spectra of MCC typical 
absorption peaks of cellulose at 1430, 1158, 1044, 1025 and 1000 cm-1 can be identified 
corresponding the results with the literature  (196). Analysis of MCCIsm mixture showed 
the characteristic peaks of microcrystalline cellulose and isomalt. The assignment of 
bands is very difficult due to several overlapping bands and intensive hydrogen bonding. 
For isomalt the followings were identified: C-C skeletal stretching band at 1087 cm-1, C–
OH stretching band for aliphatic secondary OH-group together with C–O–C ring stretch 
at 1159 cm-1 and vibration of C-O-C ring at 935 cm-1. The characteristic absorption bands 
of baicalin disappeared in spectra of BSNEDDS-MCCIsm and BSNEDDS-MCC pellets, 






Figure 34. FT-IR spectra of BSNEDDS-MCC (A), MCC (B), BSNEDDS-MCCIsm (C), 
MCCIsm (D) and baicalin (E). 400-3600 cm-1 (top) and 800-1800 cm-1 (below) 
4.5.2. Raman spectroscopy 
The above-mentioned materials and formulations were analysed by Raman spectroscopy, 
the complementary technology of IR. Vibrational characterization of the samples is 
represented in Figure 35. As baicalin possesses very low symmetry, its FT-IR and Raman 
spectra are quite similar in appearance with slightly more bands present in the IR 
spectrum and some differences in relative intensities. The difference in number and 
intensity of the bands is the consequence of the Raman scattering effect itself  (197). 
































state. Typical absorption peaks of baicalin cannot be recognized in BSNEDDS-MCCIsm 
and BSNEDDS-MCC, verifying and supporting the results of DSC and FT-IR analysis.  
 
Figure 35. Raman spectra of Baicalin, Baicalin physical mixture, MCCIsm, BSNEDDS-
MCCIsm, MCC and BSNEDDS-MCC 
4.6.In vitro dissolution study and reconstitution properties of SNEMPs 
In vitro release profiles of pure baicalin, BSNEDDS preconcentrate, BSNEDDS-
MCCIsm and BSNEDD-MCC at pH 1.2 dissolution medium are shown in Figure 36/A. 
Baicalin instantaneously released from BSNEDDS. Pure drug showed slower dissolution 
(5.77 ± 3.77%) for the initial period of 5 minutes. After the disintegration period of solid 
formulations, whole amount of baicalin was dissolved in case of BSNEDDS-MCCIsm 
and BSNEDDS-MCC within 10 minutes. Figure 36/B represents dissolution profiles of 
baicalin, BSNEDDS, BSNEDDS-MCCIsm and BSNEDD-MCC at pH 6.8 dissolution 
media. BSNEDDS dissolved total amount of its drug content within 5 minutes. 
BSNEDDS-MCCIsm has disintegrated faster compared to BSNEDDS-MCC because of 
the hydrophilic property of isomalt. Self-nanoemulsifying formulations significantly 
improved the dissolution and dissolution rate of drug comparing to pure form of API. The 
optimized solid BSNEDDS-MCCIsm released 100% of incorporated baicalin within 10 
minutes irrespective to pH value of dissolution media.  
The liquid and two solid formulae showed spontaneous nanoemulsification and there was 




reconstitution was successful because of the low PDI values in both dissolution media for 
each formulation indicating narrow droplet size distribution. It was also observed that the 
mean droplet size increased with the solidification of BSNEDDS but it was far below 200 
nm (Tbl. XXI.). On the grounds of in vitro dissolution studies and reconstitution analysis 
we can declare that remarkable dissolution improvement was achieved and total amount 
of incorporated baicalin released from homogeneous size distribution nanoemulsified 
droplets.  
Table XXI. Z-avg and PDI values of different liquid and solid formulations at pH=1.2 
and pH=6.8 measured during reconstitution analysis (Mean ± SD, n=3) 
Z-avg (nm) 
 SNEDDS BSNEDDS BSNEDDS-MCCIsm BSNEDDS-MCC 
pH=1.2 
50.41 ± 0.321 
84.93 ± 
0.323 
132.1 ± 0.152 131.1 ± 0.264 
pH=6.8 
52.84 ± 0.632 
86.67 ± 
0.295 
132.9 ± 0.208 139.3 ± 0.472 
PDI 
pH=1.2 
0.231 ± 0.01 
0.321 ± 
0.002 
0.396 ± 0.005 0.383 ± 0.002 
pH=6.8 
0.217 ± 0.01 
0.347 ± 
0.003 
























































































Preformulation is an integral part of formulation design and lays down foundation for 
transforming a new drug entity into a DDS. Numerous articles in topics of formulation 
development and solubility enhancement of baicalin were published, but the most 
important physicochemical properties influencing the pharmacokinetic and 
pharmaceutical behaviour of drugs like acid-base properties, lipophilicity, solubility, 
crystal size, crystal habit were not investigated yet in a comprehensive study. This thesis 
filled that gap and it can provide useful and necessary information for the development 
of baicalin-loaded formulations. Baicalin has low and pH-dependent solubility, low 
lipophilicity, bad flowability due to anisometric crystal habit, which predicts dubious 
processability and bioavailability. Therefore, the adequate delivery of baicalin requires a 
safe, effective, and stable pharmaceutical formulation.  
5.2.Baicalin-cyclodextrin inclusion complexation 
The present work could demonstrate for the first time that γ-cyclodextrin can enhance 
remarkably the low solubility of baicalin compared to parent α-, and β-CDs and their 
derivates. There is a different bonding and docking pattern with γ-CD, which can be 
explained in terms of the diameter, related to the respective 7 and 8 glucopyranose units 
in - and -CD. The difference is that -CD provides an extra beneficial –OH group for 
baicalin’s carbonyl group. The study of Li et al. didn’t investigate more CDs, just HP-β-
cyclodextrin was used  (198). The research aimed to characterize the effect of preparation 
method for the delivery of complexed baicalin via supercritical fluid encapsulation and 
solution mixing. They found more favourable properties in case of complexation (e.g. 
particle size and baicalin solubility) prepared by supercritical fluid extraction compared 
to conventional solution mixing. In this thesis the conventional solution mixing was 
utilized but considering the effectivity of supercritical fluid encapsulation, it would be 
interesting to check and expand this technique to γ-CD complexes in the future. Jing et 
al. investigated the complexation effect of maltosyl--CD on baicalin along with NMR 
molecular modelling studies  (199). In accordance with my findings they suggested that 




bonds and hydrophobic interactions. The CD complexation of baicalin is 
underrepresented in the scientific literature; it is promising –in the view of above-
mentioned results and considering the large number and types of various CD derivates- 
to undertake more detailed examinations for the delivery of baicalin and other 
phytopharmacons.  
5.3.Liquid Self-nanoemulsifying Drug Delivery Systems 
Self-nanoemulsifying systems are able to create colloid dispersion in vivo and deliver the 
molecule entrapped in nanodroplets to the place of absorption. A thorough and detailed 
analysis is needed to fulfil all critical quality requirements of self-emulsifying systems 
like drug loading, droplet size, Zeta-potential, long-term stability and dissolution. The 
selection of oil, emulgent and co-emulgent is also plays a prominent role. The formulation 
optimization of baicalin-loaded preconcentrates was carried out using face-centered 
experimental design. I attach great importance to the mathematical description of various 
phenomena, because they can be quantitatively characterized and disguised interactions 
can be also highlighted. Oil:surface active agent ratio and emulgent:co-emulgent ratio 
had a significant impact on all critical quality attributes of nanodroplets. The optimization 
and formulation development of BSNEDDS resulted in a 40-times solubility 
enhancement and significant dissolution improvement in case of baicalin. For the very 
first time, our research group captured these nanodroplets by AFM imaging. The sample 
preparation was a great challenge, which stems from two facts: 1. the tip of cantilever 
removed the weakly bonded droplets from sample surface. 2. The droplets were extremely 
exposed to coalescence due to the high surface energies. Freeze-drying and the use of 
liquid N2 eliminated these undesired phenomena. The self-emulsifying approach seems 
to be very promising, therefore, the quality control, scaling up, industrial implementation, 
regulatory aspects must be clarified in the future.  
5.4.Self-nanoemulsifying matrix pellets  
Self-emulsifying matrix pellets combine the benefits of liquid SEDDS (e.g. enhanced 
solubility and bioavailability, improved dissolution) with those of solid dosage forms (e.g. 
higher stability and reproducibility, better patient compliance, easier administration, 




successful development. During my experiments, MCC demonstrated the most desired 
properties; it showed adequate oil adsorbing capacity (more than 1.5-times its own 
weight), nevertheless, it released the bonded drug rapidly in the dissolution medium. The 
preparation of spherical pellets possessing acceptable physical characteristics was also 
possible. One of the greatest challenges was the selection of ideal powder/oily 
preconcentrate ratio for extrusion-spheronization; as the ratio was increased, so decreased 
the physical stability and processability; the result of lower ratio was a sticky, paste-like 
extrudate, which gave during spheronization process undesired pellets with high diameter 
and high friability. The application of isomalt slightly accelerated the disintegration time 
of pellets due to its hydrophilic nature, however, the oil adsorbing capacity of MCC-Ism 
powder mixture was significantly decreased, which is not beneficial from the point of 
view drug loading. The ideal mass ratio was 1/3-1/3-1/3 in case of BSNEDDS-MCC-Ism 
and 1/2-1/2 in case of BSNEDDS-MCC, respectively. BNSEDDS-MCC as well as 
BSNEDDS-MCCIsm revealed remarkable dissolution improvement and after 
disintegration of matrix pellets nanodroplets were generated.  
5.5.Comparison of baicalin-CD inclusion complexes and baicalin-loaded 
SNEDDS 
Considering the experimental data, it can be concluded that both the cyclodextrin 
complexation and the nanoemulsification remarkably enhanced the poor water solubility 
of baicalin, which is one of the most noteworthy result in this thesis. However, the extent 
of solubility improvement is different in favour of the lipid-based system. As we talk 
about two totally different formulation approach and the fundamental physicochemical 
mechanisms are also working another way, this result is not surprising. It is a possible 
future direction to extend the investigated CD candidates to realize higher water solubility 
gain and better stability. The comparison of formulated dosage forms -which have a great 
impact on patient compliance and industrial feasibility- demonstrates that the lipid-based 
direction is further advanced than the cyclodextrin-based DDS. In case of SNEDDS, the 
solidification and the preparation of matrix pellets having good flowability, stability, and 
in vitro dissolution are already performed. Nevertheless, a lyophilisation and/or spray 
drying step is necessary regarding the CD research direction to develop a stable and 




studies; how can the formulations perform in living organisms with the above detailed 
solubility and permeability improvement? 
5.6.Comparison the two formulations presented in the thesis with the 
formulations already published in scientific literature 
In Table II a detailed summary can be found about the innovative formulation possibilities 
for enhancing the oral bioavailability of baicalin. Indicative examples could be: solid 
dispersion, liposomes, mixed micelle system or thermosensitive hydrogel. It is clear that 
each examined innovative formulation can enhance the solubility and/or permeability of 
baicalin. However, the applied methods and excipients, stability of formulation, costs, 
industrial feasibility, expected patient-compliance and possible administration route are 
different. Liposomes, mixed micelle systems, nanoparticles are prone to stability issues, 
and the industrial scaling-up can be also a challenging task. Nanoemulsions, 
microemulsion and cyclodextrin complexes as liquid DDS demonstrate limited stability, 
the patient-compliance is also questionable, and sustainable packaging devices are 
needed. In case of baicalin this is the first research, which aimed to create solidified self-
emulsifying system. Patient-compliance, diverse dosage forms (capsule, tablet, sachet, 
straw), ease to scaling-up, modified release, appropriate stability are all the advantages of 
pharmaceutical pellets. The solidified nanoemulsion-based system demonstrated in this 
thesis may be eligible to fit in the exacting requirements of industrial sector and modern, 













The main objective of this work was to formulate and develop baicalin-loaded DDS in 
order to counterbalance the negative physicochemical and pharmaceutical properties of 
baicalin. All of the proposed goals were achieved in this study and many further 
relationships were identified and analysed. In the introduction as well as in the 
experimental section several challenges and questions were highlighted, which are 
fundamental, in my view, for the quality control and successful formulation of 
cyclodextrin and nanoemulsion-based DDS. Based on the results, the following 
conclusion can be drawn: 
1. Baicalin has promising pharmacological effects, but it demonstrates low water 
solubility and low lipophilicity, which hampers its oral bioavailability (BCS IV). 
Significant, pH-dependent solubility was found, which can be explained by the 
fact that the molecule has three acidic functional groups (pKa1: 4.21, pKa2: 8.56,  
pKa3: >14). The neutral (transportable) form is dominant up to pH 4.2, but in acidic 
environment its solubility is so low, that the oral delivery of baicalin might be 
problematic. However, in case of biorelevant conditions (FaSSGF), the presence 
of neutral emulsifying agents and fatty acids had a significant positive impact on 
the solubility of baicalin; this beneficial drug-food interaction could be exhausted 
in liberation and absorption processes (drug intake with/after meal). The molecule 
decomposes above 50 °C and in alkaline solutions, which are restrictive factors 
considering further processability.  
2. Six different CD derivates were examined to study the solubility enhancement of 
baicalin along with stability and geometry of inclusion complexes. Molecular 
modelling analysis pointed out different binding patterns and complexation 
energy for each baicalin-CD complex. In accordance with the previous 
hypothesis, thermodynamically the most favourable complex proved to be 
baicalin-γ-CD host-guest complex (ΔE = − 181.5 kJ mol−1), which fact was 
confirmed by phase-solubility (≈ 5.5 times solubility enhancement) and NMR 
spectroscopic measurements. The preliminary studies showed that it makes sense 





3. Dissolution kinetics of baicalin was improved in a self-nanoemulsifying system 
taking different types of oils, surfactants, co-surfactants, and ideal ratio of 
components into consideration, based on response surface methodology, using a 
central composite experimental design. The best composition contains Peceol™ 
(14.29%, w/w), Kolliphor® EL (57.14%, w/w), and Transcutol® P (28.57%, w/w). 
Droplet size was measured by DLS method and verified by AFM, together with 
morphological characterization. A new sample preparation method gave the 
opportunity to analyse the freeze-dried samples without any signs of aggregation 
of droplets. Droplet size after dispergation of BSNEDDS pre-concentrate was 
highly desirable, with 86.75 ± 0.3553 nm; the Zeta-potential was -24.3 ± 1.44 mV, 
which is also acceptable. The results proved that the low aqueous solubility and 
dissolution rate of baicalin can be significantly improved by the optimized 
BSNEDDS formula. The pre-concentrate showed very rapid emulsification 
(within seconds) and nanosized droplets were generated. 
4. Transformation of liquid BSNEDDS preconcentrate to different solid carriers and 
the preparation of self-nanoemulsifying matrix pellets were carried out by 
extrusion-spheronization method. The selection of MCC and isomalt as carriers 
was an ideal choice as both of the pellet formulas prepared using them 
demonstrated sufficient physical characteristics. BSNEDDS-MCC and 
BSNEDDS-MCCIsm had spherical shape, narrow particle size distribution, 
excellent flow, low friability. The only difference was the slightly accelerated 
disintegration time in case of BSNEDDS-MCCIsm because of the hydrophilic 
nature of isomalt. FT-IR, Raman vibrational spectroscopic characterization 
techniques demonstrated the amorphous physical state of baicalin in solid 
formulations, which is partially responsible for the enhanced dissolution 
behaviour. In-vitro dissolution studies showed significant, pH-independent 
dissolution rate and saturation solubility improvement (100%, within 15 minutes). 
On reconstitution investigations it was pointed out that baicalin is released from 
the solid dosage form in colloidal dispersion that had an average size of 130-140 
nm. These results indicate the significance of solid self-nanoemulsifying systems, 
which are suitable for the oral delivery of pharmacons possessing low solubility 





One of the most tremendous challenges faced by pharmaceutical scientists is the 
improvement of poor solubility and/or permeability and the concomitant low 
bioavailability of new chemical entities. Baicalin is a bioactive flavonoid extracted from 
the root of Scutellaria Baicalensis. Numerous pharmacological effects of this 
phytopharmacon were reported (e.g. antioxidant, anxiolytic), nevertheless the 
inappropriate biopharmaceutical properties hamper its oral delivery. In this thesis the 
physicochemical analysis of baicalin was demonstrated along with the development and 
examination of suitable oral DDS, which are able to counterbalance the challenging 
pharmaceutical attributes of this natural herb medicine. Firstly, the thorough 
characterization of baicalin was carried out in terms of acid-base properties, biorelevant 
solubility, lipophilicity, crystal size and crystal habit. Secondly, six baicalin-cyclodextrin 
inclusion complexes, as possible carriers, were formulated and examined with different 
theoretical and experimental methods. NMR, thermodynamical calculations and 
molecular modelling indicated that γ-CD is suitable as a host molecule for baicalin and 
significantly improves its solubility. In the third section the focus was put on self-
nanoemulsifying systems, where response surface methodology and desirability approach 
were used to select the best composition. More than 40-times solubility improvement was 
achieved with the optimized self-nanoemulsifying formulation correlated to solubility of 
baicalin in distilled water. At this stage, a new sample preparation method was developed 
for the AFM imaging of reconstituted baicalin-loaded nanodroplets. In phase four the 
study aimed to highlight how to transform oily preconcentrates with high viscosity to 
solid carriers, and is it possible to create matrix pellets made of oily components 
demonstrating acceptable physical characteristics? The results pointed out that the 
preconcentrate could be effectively adsorbed to MCC and isomalt-based carriers and the 
low aqueous solubility and dissolution rate of baicalin can be significantly improved by 
self-nanoemulsifying matrix pellets. The amorphous state of baicalin and the emulsifying 
agents together are responsible for the enhanced dissolution rate. It can be concluded that 
despite the challenging pharmaceutical properties of baicalin, its dissolution and 
solubility can be successfully enhanced with cyclodextrins and self-emulsifying systems. 
The relationships and data described herein extend beyond baicalin itself, they could be 





A gyógyszerkutatók egyik legnagyobb kihívása napjainkban az új kémiai entitások rossz 
vízoldhatóságának és/vagy permeábilitásának, valamint az ebből következő alacsony 
biohasznosulásának javítása. A bajkalin egy, a Scutellaria baicalensis gyökerében 
található bioaktív flavonoid. Számos farmakológiai hatását leírták (pl. antioxidáns, 
anxiolítikus), azonban a nem kielégítő biohasznosíthatóság nehezíti orális alkalmazását. 
A doktori munkámban a bajkalin fiziko-kémiai elemzése, valamint a molekula kihívást 
jelentő gyógyszerészeti tulajdonságainak az ellensúlyozására alkalmas orális 
gyógyszerhordozó rendszerek fejlesztése és vizsgálata került bemutatásra. Elsőként a 
fitofarmakon részletes sav-bázis, bioreleváns oldhatóság, lipofilitás, kristály méret és 
kristály habitus analízisét végeztem el. Ezt követően hat bajkalin-ciklodextrin 
zárványkomplexet formuláltam és tanulmányoztam különböző elméleti és experimentális 
módszerekkel. NMR, termodinamikai számítások és molekulamodellezések 
alátámasztották, hogy a γ-CD megfelelő a bajkalin komplexálására és szignifikánsan 
javítja annak oldhatóságát. Munkám harmadik fázisa az ön-nanoemulgeáló rendszerekre 
fókuszált, ahol a megfelelő összetétel kiválasztása az eredményfelület módszeren és 
kívánatossági függvényszámításokon alapult. A hatóanyag több mint 40-szeres 
oldhatóságjavulást mutatott az optimalizált ön-nanoemulgeálódó formuláció esetén a 
desztillált vízben mért értékhez viszonyítva. Ehhez a részhez kapcsolódott egy új 
mintaelőkészítési eljárás kidolgozása a rekonstituált bajkalin tartalmú nanocseppek AFM 
felvételeihez. A negyedik részben célom volt górcső alá venni, hogy miként lehetséges 
nagy viszkozitású olajos prekoncentrátumok felvitele szilárd hordozókra, és lehetséges-e 
megfelelő fizikai tulajdonságokkal rendelkező mátrixpelletek előállítása olajos 
komponensekből? Eredményeim alapján elmondható, hogy a prekoncentrátum sikeresen 
adszorbeálható MCC és izomalt alapú hordozókra, továbbá a bajkalin alacsony 
vízoldhatóság és kioldódása javítható ön-nanoemulgeálódó mátrixpelletek 
alkalmazásával. A kioldódási arány fokozódásáért a molekula amorf állapota és a 
jelenlévő emulgensek együttesen felelősek. Összegzésként ki szeretném emelni, hogy a 
bajkalin kihívást jelentő fiziko-kémiai tulajdonságai ellenére a kioldódása és oldhatósága 
sikeresen növelhető ciklodextrinekkel és önemulgeáló rendszerekkel. A feltárt 
összefüggések és adatok túlmutatnak a vizsgált hatóanyagon, további felhasználásuk is 
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